|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/28/12 Ziopharm Oncology Inc 10-Q/A 6/30/12 50:3.1M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q/A Amendment to Quarterly Report HTML 29K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 18K
32: R1 Document and Entity Information HTML 37K
23: R2 Balance Sheets HTML 112K
30: R3 Balance Sheets (Parenthetical) HTML 39K
34: R4 Statements Of Operations HTML 67K
46: R5 Statement Of Stockholders' Equity HTML 66K
24: R6 Statement Of Stockholders' Equity (Parenthetical) HTML 18K
29: R7 Statements of Cash Flows HTML 142K
21: R8 Business HTML 26K
15: R9 Summary of Significant Accounting Policies HTML 19K
47: R10 Collaborations and Alliances HTML 21K
36: R11 Fair Value Measurements HTML 38K
35: R12 Net Loss per Share HTML 23K
40: R13 Related Party Transactions HTML 22K
41: R14 Commitments and Contingencies HTML 53K
39: R15 Warrants HTML 52K
42: R16 Common Stock HTML 19K
31: R17 Stock-Based Compensation HTML 48K
33: R18 Fair Value Measurements (Tables) HTML 27K
38: R19 Net Loss per Share (Tables) HTML 22K
50: R20 Warrants (Tables) HTML 42K
44: R21 Stock-Based Compensation (Tables) HTML 52K
26: R22 Business - Additional Information (Detail) HTML 23K
37: R23 Collaborations and Alliances - Additional HTML 24K
Information (Detail)
28: R24 Assets and Liabilities Measured at Fair Value on HTML 26K
Recurring Basis (Detail)
13: R25 Potential Dilutive Shares Excluded from HTML 26K
Computation of Diluted Net Loss Per Share (Detail)
45: R26 Related Party Transactions - Additional HTML 28K
Information (Detail)
48: R27 Commitments and Contingencies - Additional HTML 121K
Information (Detail)
18: R28 Number of Warrants Outstanding (Detail) HTML 21K
17: R29 Warrants - Additional Information (Detail) HTML 74K
19: R30 Assumptions Used In Binomial Valuation Model and HTML 25K
Black-Scholes Valuation Model (Detail)
20: R31 Warrant Exercise (Detail) HTML 32K
22: R32 Common Stock - Additional Information (Detail) HTML 34K
11: R33 Stock-Based Compensation Expense on All Employee HTML 23K
and Non-Employee Awards (Detail)
43: R34 Stock-Based Compensation - Additional Information HTML 31K
(Detail)
25: R35 Fair Value of Stock Options Assumptions Using HTML 34K
Black-Scholes Option Valuation Model (Detail)
27: R36 Stock Option Activity Under Stock Option Plan HTML 83K
(Detail)
14: R37 Summary of Unvested Restricted Stock (Detail) HTML 46K
49: XML IDEA XML File -- Filing Summary XML 74K
16: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 392K
5: EX-101.INS XBRL Instance -- ziop-20120630 XML 731K
7: EX-101.CAL XBRL Calculations -- ziop-20120630_cal XML 109K
8: EX-101.DEF XBRL Definitions -- ziop-20120630_def XML 650K
9: EX-101.LAB XBRL Labels -- ziop-20120630_lab XML 966K
10: EX-101.PRE XBRL Presentations -- ziop-20120630_pre XML 726K
6: EX-101.SCH XBRL Schema -- ziop-20120630 XSD 147K
12: ZIP XBRL Zipped Folder -- 0001144204-12-048414-xbrl Zip 101K
| <?xml version="1.0" standalone="yes" encoding="windows-1252"?> | |||||||||||||||||||||
| <!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1 http://www.edgar-online.com/ --> | |||||||||||||||||||||
| <!-- Version: 6.17.6 --> | |||||||||||||||||||||
| <!-- Round: 3 --> | |||||||||||||||||||||
| <!-- Creation date: 2012-08-22T19:57:32Z --> | |||||||||||||||||||||
| <!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. --> | |||||||||||||||||||||
| <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ziop="http://www.ziopharm.com/20120630"> | |||||||||||||||||||||
| <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="ziop-20120630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase"/> | |||||||||||||||||||||
| <ziop:AssetAcquiredOtherThanThroughBusinessCombinationCashPaid contextRef="eol_PE83398---1210-Q0004_STD_0_20061103_0_499645x505333_553597x603797" unitRef="iso4217_USD" decimals="-5" id="id_123082_22A73969-B48A-425B-8537-C6363641173C_3001_0"> 1100000 </ziop:AssetAcquiredOtherThanThroughBusinessCombinationCashPaid> | |||||||||||||||||||||
| <ziop:AssetAcquiredOtherThanThroughBusinessCombinationCashPaid contextRef="eol_PE83398---1210-Q0004_STD_0_20061103_0_499645x511481_553597x603797" unitRef="iso4217_USD" decimals="-3" id="id_123082_22A73969-B48A-425B-8537-C6363641173C_4001_1"> 100000 </ziop:AssetAcquiredOtherThanThroughBusinessCombinationCashPaid> | |||||||||||||||||||||
| <ziop:MilestonePaymentsMaximumAmount contextRef="eol_PE83398---1210-Q0004_STD_0_20061103_0_499645x533554_553597x603797" unitRef="iso4217_USD" decimals="-6" id="id_123082_22A73969-B48A-425B-8537-C6363641173C_5001_2"> 8000000 </ziop:MilestonePaymentsMaximumAmount> | |||||||||||||||||||||
| <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE83398---1210-Q0004_STD_0_20070223_0" unitRef="iso4217_USD_per_Right" decimals="2" id="id_123082_02A7207C-06A9-47CF-BE9B-0CBAF0BD0989_1001_2"> 5.75 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights> | |||||||||||||||||||||
| <ziop:CollaborativeArrangementAgreementResearchFundingPeriod contextRef="eol_PE83398---1210-Q0004_STD_0_20110307_0" id="id_123082_6653E2DC-2DAE-4D3A-83A0-C934D31DC4A3_1001_0"> P75M </ziop:CollaborativeArrangementAgreementResearchFundingPeriod> | |||||||||||||||||||||
| <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE83398---1210-Q0004_STD_0_20050531_0" unitRef="iso4217_USD_per_Right" decimals="2" id="id_123082_02A7207C-06A9-47CF-BE9B-0CBAF0BD0989_1002_2"> 3.93 </us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights> | |||||||||||||||||||||
| <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20050531_0_512768x505866" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_3003_4"> 4.75 </us-gaap:SaleOfStockPricePerShare> | |||||||||||||||||||||
| <ziop:WarrantResetPrice contextRef="eol_PE83398---1210-Q0004_STD_0_20050531_0_512768x505866" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_3003_5"> 4.69 </ziop:WarrantResetPrice> | |||||||||||||||||||||
| <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20120729_0" unitRef="shares" decimals="INF" id="id_123082_71E40D9B-273D-42D3-8940-30A05BBAED18_2_500005"> 79567946 </dei:EntityCommonStockSharesOutstanding> | |||||||||||||||||||||
| <ziop:MilestonePaymentsMaximumAmount contextRef="eol_PE83398---1210-Q0004_STD_0_20041015_0_553597x603794" unitRef="iso4217_USD" decimals="-5" id="id_123082_403F8303-BB34-47EC-BCEB-EE495E65A537_5001_0"> 4000000 </ziop:MilestonePaymentsMaximumAmount> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE83398---1210-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3002_34"> 130282000 </us-gaap:CashAndCashEquivalentsAtCarryingValue> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife contextRef="eol_PE83398---1210-Q0004_STD_0_20110630_0_504957x513639_510728x559133" unitRef="Year" decimals="2" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_1002_2"> 0.92 </ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionStockVolatility contextRef="eol_PE83398---1210-Q0004_STD_0_20110630_0_504957x513639_510728x559133" unitRef="pure" decimals="2" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_1002_4"> 0.45 </ziop:ClassOfWarrantOrRightFairValueAssumptionStockVolatility> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate contextRef="eol_PE83398---1210-Q0004_STD_0_20110630_0_504957x513639_510728x559133" unitRef="pure" decimals="4" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_1002_0"> 0.0018 </ziop:ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife contextRef="eol_PE83398---1210-Q0004_STD_0_20110630_0_504957x514053_510728x559133" unitRef="Year" decimals="2" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_2002_3"> 3.43 </ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionStockVolatility contextRef="eol_PE83398---1210-Q0004_STD_0_20110630_0_504957x514053_510728x559133" unitRef="pure" decimals="2" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_2002_5"> 0.97 </ziop:ClassOfWarrantOrRightFairValueAssumptionStockVolatility> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate contextRef="eol_PE83398---1210-Q0004_STD_0_20110630_0_504957x514053_510728x559133" unitRef="pure" decimals="4" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_2002_1"> 0.0101 </ziop:ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield contextRef="eol_PE83398---1210-Q0004_STD_0_20110630_0_510728x559133" unitRef="pure" decimals="2" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_2_6"> 0.00 </ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield> | |||||||||||||||||||||
| <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_4"> 9051000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_688607D2-5409-485C-B6C4-C2CED35501B7_1001_9"> 3678000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant> | |||||||||||||||||||||
| <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_33"> 304219000 </us-gaap:AdditionalPaidInCapitalCommonStock> | |||||||||||||||||||||
| <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_8"> 824000 </us-gaap:OtherAssetsNoncurrent> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_688607D2-5409-485C-B6C4-C2CED35501B7_1001_7"> 3124387 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_36"> 75636000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:CommitmentsAndContingencies contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_21"/> | |||||||||||||||||||||
| <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-5" id="id_123082_9E2F3C71-35F6-4F7C-8E4E-73714C1D167F_1001_0"> 10300000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_927AFDF7-3041-4A1F-AD62-57FD133217B2_1001_3"> 8137000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1> | |||||||||||||||||||||
| <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_30"> 250000000 </us-gaap:CommonStockSharesAuthorized> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_12BDD485-E087-448A-968A-4816AF9E7BE3_1001_7"> 3.40 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice> | |||||||||||||||||||||
| <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_32"> 79625290 </us-gaap:CommonStockSharesOutstanding> | |||||||||||||||||||||
| <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_11A70944-2DCF-4DFE-831F-FE56844EB2DD_1_400002"> 11268678 </us-gaap:ClassOfWarrantOrRightOutstanding> | |||||||||||||||||||||
| <us-gaap:OtherAdditionalCapital contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_34"> 7012000 </us-gaap:OtherAdditionalCapital> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_688607D2-5409-485C-B6C4-C2CED35501B7_1001_6"> 5340550 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber> | |||||||||||||||||||||
| <us-gaap:Liabilities contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_20"> 46744000 </us-gaap:Liabilities> | |||||||||||||||||||||
| <us-gaap:AccountsPayableCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_12"> 1470000 </us-gaap:AccountsPayableCurrent> | |||||||||||||||||||||
| <us-gaap:DeferredRevenueCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_14"> 800000 </us-gaap:DeferredRevenueCurrent> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_6EDA9770-F1A3-4916-8E46-CFBB07A02E77_1001_5"> 4.34 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_35"> 235675000 </us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage> | |||||||||||||||||||||
| <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_19"> 25472000 </us-gaap:OtherLiabilitiesNoncurrent> | |||||||||||||||||||||
| <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_25"> 30000000 </us-gaap:PreferredStockSharesAuthorized> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_C938AA4F-0000-484E-957C-17E4E2DCA85F_2001_1"> 109455000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure> | |||||||||||||||||||||
| <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-5" id="id_123082_5560BDAE-A4C9-47A2-850E-646FA5DA2211_1_0"> 235700000 </us-gaap:RetainedEarningsAccumulatedDeficit> | |||||||||||||||||||||
| <us-gaap:Assets contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_9"> 122380000 </us-gaap:Assets> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_12BDD485-E087-448A-968A-4816AF9E7BE3_1001_5"> 4.10 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_12BDD485-E087-448A-968A-4816AF9E7BE3_1001_6"> 4.10 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice> | |||||||||||||||||||||
| <us-gaap:DepositsAssetsNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_7"> 132000 </us-gaap:DepositsAssetsNoncurrent> | |||||||||||||||||||||
| <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_24"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare> | |||||||||||||||||||||
| <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_37"> 122380000 </us-gaap:LiabilitiesAndStockholdersEquity> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_927AFDF7-3041-4A1F-AD62-57FD133217B2_1001_2"> 10212000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_2"> 110391000 </us-gaap:CashAndCashEquivalentsAtCarryingValue> | |||||||||||||||||||||
| <us-gaap:CommonStockSharesIssued contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_31"> 79625290 </us-gaap:CommonStockSharesIssued> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_5A5F1688-5917-4972-9E05-E3C88457EC1F_1001_5"> 1029848 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber> | |||||||||||||||||||||
| <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_13"> 15502000 </us-gaap:AccruedLiabilitiesCurrent> | |||||||||||||||||||||
| <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_15"> 4000 </us-gaap:DeferredRentCreditCurrent> | |||||||||||||||||||||
| <us-gaap:LiabilitiesCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_16"> 17776000 </us-gaap:LiabilitiesCurrent> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_688607D2-5409-485C-B6C4-C2CED35501B7_1001_5"> 5397154 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> | |||||||||||||||||||||
| <us-gaap:CommonStockValue contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_28"> 80000 </us-gaap:CommonStockValue> | |||||||||||||||||||||
| <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_18"> 363000 </us-gaap:DeferredRentCreditNoncurrent> | |||||||||||||||||||||
| <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_29"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare> | |||||||||||||||||||||
| <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_17"> 3133000 </us-gaap:DeferredRevenueNoncurrent> | |||||||||||||||||||||
| <us-gaap:AssetsCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_5"> 119442000 </us-gaap:AssetsCurrent> | |||||||||||||||||||||
| <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_27"> 0 </us-gaap:PreferredStockSharesOutstanding> | |||||||||||||||||||||
| <us-gaap:PreferredStockSharesIssued contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_26"> 0 </us-gaap:PreferredStockSharesIssued> | |||||||||||||||||||||
| <us-gaap:PreferredStockValue contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_23"/> | |||||||||||||||||||||
| <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_1_6"> 1982000 </us-gaap:PropertyPlantAndEquipmentNet> | |||||||||||||||||||||
| <ziop:WarrantLiabilitiesFairValueDisclosure contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_C938AA4F-0000-484E-957C-17E4E2DCA85F_2001_2"> 25472000 </ziop:WarrantLiabilitiesFairValueDisclosure> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_504957x513639_510728x580425" unitRef="Year" decimals="2" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_1001_2"> 2.44 </ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionStockVolatility contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_504957x513639_510728x580425" unitRef="pure" decimals="2" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_1001_4"> 0.70 </ziop:ClassOfWarrantOrRightFairValueAssumptionStockVolatility> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_504957x513639_510728x580425" unitRef="pure" decimals="4" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_1001_0"> 0.0037 </ziop:ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate> | |||||||||||||||||||||
| <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_506936x504830" unitRef="shares" decimals="INF" id="id_123082_11A70944-2DCF-4DFE-831F-FE56844EB2DD_1001_400001"> 3217969 </us-gaap:ClassOfWarrantOrRightOutstanding> | |||||||||||||||||||||
| <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_506936x598178" unitRef="shares" decimals="INF" id="id_123082_11A70944-2DCF-4DFE-831F-FE56844EB2DD_2001_400000"> 8050709 </us-gaap:ClassOfWarrantOrRightOutstanding> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x500343" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_3007_1000011"> -235675000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x501348" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_3003_700011"> 80000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:SharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x501348" unitRef="shares" decimals="INF" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_3003_600011"> 79625290 </us-gaap:SharesOutstanding> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x504626" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_3006_900011"> 7012000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x530731" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_3005_800011"> 304219000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_507611x603123" unitRef="iso4217_USD" decimals="-5" id="id_123082_0B1F11AA-23C7-41FC-A063-C0C288783307_2001_2"> 8200000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent> | |||||||||||||||||||||
| <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_508454x557649" unitRef="iso4217_USD" decimals="-5" id="id_123082_0D5713C8-0E5E-4BA8-B504-645CEA5A68CC_2001_0"> 6400000 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_510142x508799" unitRef="iso4217_USD" decimals="-3" id="id_123082_C938AA4F-0000-484E-957C-17E4E2DCA85F_2002_1"> 109455000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure> | |||||||||||||||||||||
| <ziop:WarrantLiabilitiesFairValueDisclosure contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_510142x511009" unitRef="iso4217_USD" decimals="-3" id="id_123082_C938AA4F-0000-484E-957C-17E4E2DCA85F_2003_2"> 25472000 </ziop:WarrantLiabilitiesFairValueDisclosure> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_510728x580425" unitRef="Year" decimals="0" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_1_7"> 12 </ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_510728x580425" unitRef="pure" decimals="2" id="id_123082_C0784F2D-73DF-4CA7-B371-71ABA25A4C4A_1_6"> 0.00 </ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield> | |||||||||||||||||||||
| <ziop:MilestonePaymentsMaximumAmount contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_553597x603793" unitRef="iso4217_USD" decimals="-5" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_8001_10"> 4500000 </ziop:MilestonePaymentsMaximumAmount> | |||||||||||||||||||||
| <ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_553597x603793_588157x537108" unitRef="shares" decimals="INF" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_9001_7"> 12556 </ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber> | |||||||||||||||||||||
| <ziop:MilestonePaymentsMaximumAmount contextRef="eol_PE83398---1210-Q0004_STD_0_20120630_0_553597x603795" unitRef="iso4217_USD" decimals="0" id="id_123082_985EAD3E-A512-4830-B0CB-B16BD69732B9_4001_3"> 775000 </ziop:MilestonePaymentsMaximumAmount> | |||||||||||||||||||||
| <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20041231_0_553597x603793" unitRef="iso4217_USD_per_shares" decimals="3" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_8005_3"> 0.002 </us-gaap:SaleOfStockPricePerShare> | |||||||||||||||||||||
| <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20041231_0_553597x603794" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_403F8303-BB34-47EC-BCEB-EE495E65A537_5005_3"> 0.02 </us-gaap:SaleOfStockPricePerShare> | |||||||||||||||||||||
| <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20061231_0_512768x505866" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_3004_4"> 4.63 </us-gaap:SaleOfStockPricePerShare> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0" unitRef="Year" decimals="0" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_2001_8"> 5 </ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedLife> | |||||||||||||||||||||
| <ziop:CommonStockWarrantsFairValue contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-5" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_2001_5"> 22900000 </ziop:CommonStockWarrantsFairValue> | |||||||||||||||||||||
| <ziop:ClassOfWarrantTerm contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_2001_4"> P5Y </ziop:ClassOfWarrantTerm> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0" unitRef="pure" decimals="2" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_2001_9"> 0.00 </ziop:ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionStockVolatility contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0" unitRef="pure" decimals="2" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_2001_6"> 1.05 </ziop:ClassOfWarrantOrRightFairValueAssumptionStockVolatility> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0" unitRef="pure" decimals="4" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_2001_7"> 0.0214 </ziop:ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate> | |||||||||||||||||||||
| <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0_512768x505866" unitRef="iso4217_USD_per_shares" decimals="3" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_3005_6"> 1.825 </us-gaap:SaleOfStockPricePerShare> | |||||||||||||||||||||
| <ziop:WarrantResetPrice contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0_512768x505866" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_3005_8"> 4.25 </ziop:WarrantResetPrice> | |||||||||||||||||||||
| <ziop:WarrantResetPrice contextRef="eol_PE83398---1210-Q0004_STD_0_20091231_0_512768x531939" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_4005_10"> 3.93 </ziop:WarrantResetPrice> | |||||||||||||||||||||
| <ziop:MilestonePaymentsMaximumAmount contextRef="eol_PE83398---1210-Q0004_STD_0_20100129_0_553597x603799" unitRef="iso4217_USD" decimals="-5" id="id_123082_5EA3AFB4-6CDB-4D09-A80A-78C56FE9C2A6_4001_0"> 18300000 </ziop:MilestonePaymentsMaximumAmount> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE83398---1210-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_5001_33"> 60392000 </us-gaap:CashAndCashEquivalentsAtCarryingValue> | |||||||||||||||||||||
| <ziop:MilestonePaymentsMaximumAmount contextRef="eol_PE83398---1210-Q0004_STD_0_20111213_0_553597x603802" unitRef="iso4217_USD" decimals="-5" id="id_123082_8EF51F28-81E2-45E0-BC37-3C26952D800E_5001_0"> 19700000 </ziop:MilestonePaymentsMaximumAmount> | |||||||||||||||||||||
| <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_4"> 1313000 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent> | |||||||||||||||||||||
| <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_33"> 246519000 </us-gaap:AdditionalPaidInCapitalCommonStock> | |||||||||||||||||||||
| <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_8"> 771000 </us-gaap:OtherAssetsNoncurrent> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_688607D2-5409-485C-B6C4-C2CED35501B7_2001_8"> 2911186 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_36"> 71607000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:CommitmentsAndContingencies contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_21"/> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_927AFDF7-3041-4A1F-AD62-57FD133217B2_2001_4"> 4232000 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1> | |||||||||||||||||||||
| <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_30"> 250000000 </us-gaap:CommonStockSharesAuthorized> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_12BDD485-E087-448A-968A-4816AF9E7BE3_2001_8"> 3.21 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice> | |||||||||||||||||||||
| <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_32"> 69206044 </us-gaap:CommonStockSharesOutstanding> | |||||||||||||||||||||
| <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_11A70944-2DCF-4DFE-831F-FE56844EB2DD_2_500002"> 13117264 </us-gaap:ClassOfWarrantOrRightOutstanding> | |||||||||||||||||||||
| <us-gaap:OtherAdditionalCapital contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_34"> 12611000 </us-gaap:OtherAdditionalCapital> | |||||||||||||||||||||
| <us-gaap:ReceivablesNetCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_3"> 79000 </us-gaap:ReceivablesNetCurrent> | |||||||||||||||||||||
| <us-gaap:Liabilities contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_20"> 36501000 </us-gaap:Liabilities> | |||||||||||||||||||||
| <us-gaap:AccountsPayableCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_12"> 1727000 </us-gaap:AccountsPayableCurrent> | |||||||||||||||||||||
| <us-gaap:DeferredRevenueCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_14"> 800000 </us-gaap:DeferredRevenueCurrent> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_6EDA9770-F1A3-4916-8E46-CFBB07A02E77_2001_1"> 4.34 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_35"> 187592000 </us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage> | |||||||||||||||||||||
| <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_19"> 19425000 </us-gaap:OtherLiabilitiesNoncurrent> | |||||||||||||||||||||
| <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_25"> 30000000 </us-gaap:PreferredStockSharesAuthorized> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_C938AA4F-0000-484E-957C-17E4E2DCA85F_1001_3"> 103736000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure> | |||||||||||||||||||||
| <us-gaap:Assets contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_9"> 108108000 </us-gaap:Assets> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_12BDD485-E087-448A-968A-4816AF9E7BE3_2001_1"> 4.08 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice> | |||||||||||||||||||||
| <us-gaap:DepositsAssetsNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_7"> 91000 </us-gaap:DepositsAssetsNoncurrent> | |||||||||||||||||||||
| <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_24"> 0.001 </us-gaap:PreferredStockParOrStatedValuePerShare> | |||||||||||||||||||||
| <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_37"> 108108000 </us-gaap:LiabilitiesAndStockholdersEquity> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_2"> 104713000 </us-gaap:CashAndCashEquivalentsAtCarryingValue> | |||||||||||||||||||||
| <us-gaap:CommonStockSharesIssued contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_31"> 69206044 </us-gaap:CommonStockSharesIssued> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_5A5F1688-5917-4972-9E05-E3C88457EC1F_2001_1"> 950906 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber> | |||||||||||||||||||||
| <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_13"> 10821000 </us-gaap:AccruedLiabilitiesCurrent> | |||||||||||||||||||||
| <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_15"> 15000 </us-gaap:DeferredRentCreditCurrent> | |||||||||||||||||||||
| <us-gaap:LiabilitiesCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_16"> 13363000 </us-gaap:LiabilitiesCurrent> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_688607D2-5409-485C-B6C4-C2CED35501B7_2001_1"> 5138486 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber> | |||||||||||||||||||||
| <us-gaap:CommonStockValue contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_28"> 69000 </us-gaap:CommonStockValue> | |||||||||||||||||||||
| <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_18"> 180000 </us-gaap:DeferredRentCreditNoncurrent> | |||||||||||||||||||||
| <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_29"> 0.001 </us-gaap:CommonStockParOrStatedValuePerShare> | |||||||||||||||||||||
| <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_17"> 3533000 </us-gaap:DeferredRevenueNoncurrent> | |||||||||||||||||||||
| <us-gaap:AssetsCurrent contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_5"> 106105000 </us-gaap:AssetsCurrent> | |||||||||||||||||||||
| <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_27"> 0 </us-gaap:PreferredStockSharesOutstanding> | |||||||||||||||||||||
| <us-gaap:PreferredStockSharesIssued contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_26"> 0 </us-gaap:PreferredStockSharesIssued> | |||||||||||||||||||||
| <us-gaap:PreferredStockValue contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_23"/> | |||||||||||||||||||||
| <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_6B75B939-B696-4CE3-BCC5-2D5ABC6669B1_2_6"> 1141000 </us-gaap:PropertyPlantAndEquipmentNet> | |||||||||||||||||||||
| <ziop:WarrantLiabilitiesFairValueDisclosure contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_C938AA4F-0000-484E-957C-17E4E2DCA85F_1001_4"> 19425000 </ziop:WarrantLiabilitiesFairValueDisclosure> | |||||||||||||||||||||
| <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_506936x504830" unitRef="shares" decimals="INF" id="id_123082_11A70944-2DCF-4DFE-831F-FE56844EB2DD_1002_500001"> 4692359 </us-gaap:ClassOfWarrantOrRightOutstanding> | |||||||||||||||||||||
| <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_506936x598178" unitRef="shares" decimals="INF" id="id_123082_11A70944-2DCF-4DFE-831F-FE56844EB2DD_2002_500000"> 8424905 </us-gaap:ClassOfWarrantOrRightOutstanding> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x500343" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_1007_1000001"> -187592000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x501348" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_1003_700001"> 69000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:SharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x501348" unitRef="shares" decimals="INF" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_1003_600001"> 69206044 </us-gaap:SharesOutstanding> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x504626" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_1006_900001"> 12611000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:StockholdersEquity contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x530731" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_1005_800001"> 246519000 </us-gaap:StockholdersEquity> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_510142x508799" unitRef="iso4217_USD" decimals="-3" id="id_123082_C938AA4F-0000-484E-957C-17E4E2DCA85F_1002_3"> 103736000 </us-gaap:CashAndCashEquivalentsFairValueDisclosure> | |||||||||||||||||||||
| <ziop:WarrantLiabilitiesFairValueDisclosure contextRef="eol_PE83398---1210-Q0004_STD_0_20111231_0_510142x511009" unitRef="iso4217_USD" decimals="-3" id="id_123082_C938AA4F-0000-484E-957C-17E4E2DCA85F_1003_4"> 19425000 </ziop:WarrantLiabilitiesFairValueDisclosure> | |||||||||||||||||||||
| <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20120120_0_508454x534907" unitRef="iso4217_USD_per_shares" decimals="3" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_3001_2"> 4.888 </us-gaap:SaleOfStockPricePerShare> | |||||||||||||||||||||
| <ziop:InvestmentOptionExercisePeriod contextRef="eol_PE83398---1210-Q0004_STD_0_20120120_0_508454x534907" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_3001_3"> P30D </ziop:InvestmentOptionExercisePeriod> | |||||||||||||||||||||
| <ziop:PublicOfferingNetPricePerShare contextRef="eol_PE83398---1210-Q0004_STD_0_20120120_0_508454x534907" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_3001_1"> 5.20 </ziop:PublicOfferingNetPricePerShare> | |||||||||||||||||||||
| <us-gaap:OperatingIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_5"> -40774000 </us-gaap:OperatingIncomeLoss> | |||||||||||||||||||||
| <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_5"> -8965000 </us-gaap:OtherNoncashIncomeExpense> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_15"> 753000 </us-gaap:IncreaseDecreaseInAccountsPayable> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_6"> 7000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <us-gaap:ContractsRevenue contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_0"> 267000 </us-gaap:ContractsRevenue> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingGainsLosses contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_7"> -8965000 </us-gaap:OtherNonoperatingGainsLosses> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_4"> 1314000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_4"> 41041000 </us-gaap:OperatingCostsAndExpenses> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareDiluted contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_10"> -0.78 </us-gaap:EarningsPerShareDiluted> | |||||||||||||||||||||
| <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_42"> 265000 </us-gaap:DebtConversionConvertedInstrumentAmount1> | |||||||||||||||||||||
| <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_27"> 78000 </us-gaap:PaymentsForRepurchaseOfCommonStock> | |||||||||||||||||||||
| <us-gaap:DepreciationAndAmortization contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_3"> 95000 </us-gaap:DepreciationAndAmortization> | |||||||||||||||||||||
| <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_26"> 849000 </us-gaap:ProceedsFromStockOptionsExercised> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_19"> -13989000 </us-gaap:NetCashProvidedByUsedInOperatingActivities> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_23"> -392000 </us-gaap:NetCashProvidedByUsedInInvestingActivities> | |||||||||||||||||||||
| <us-gaap:IncomeTaxesPaid contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_37"/> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_17"> 4733000 </us-gaap:IncreaseDecreaseInDeferredRevenue> | |||||||||||||||||||||
| <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_21"> 392000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_32"> 69890000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_18"> -5000 </us-gaap:IncreaseDecreaseInOtherDeferredLiability> | |||||||||||||||||||||
| <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_3"> 7275000 </us-gaap:GeneralAndAdministrativeExpense> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_11"> 592000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> | |||||||||||||||||||||
| <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="shares" decimals="0" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_12"> 63839723 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> | |||||||||||||||||||||
| <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_28"> 12293000 </us-gaap:ProceedsFromWarrantExercises> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareBasic contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_9"> -0.78 </us-gaap:EarningsPerShareBasic> | |||||||||||||||||||||
| <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_2"> 33766000 </us-gaap:ResearchAndDevelopmentExpense> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_31"> 84271000 </us-gaap:NetCashProvidedByUsedInFinancingActivities> | |||||||||||||||||||||
| <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="shares" decimals="0" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_11"> 63839723 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_13"> 4000 </us-gaap:IncreaseDecreaseInDepositOtherAssets> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_12"> 519000 </us-gaap:IncreaseDecreaseInOtherNoncurrentAssets> | |||||||||||||||||||||
| <us-gaap:InterestPaid contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_36"/> | |||||||||||||||||||||
| <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="shares" decimals="INF" id="id_123082_3C6D3E62-61F7-49B6-B9DB-AEB4B5755827_2_500003"> 18291650 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> | |||||||||||||||||||||
| <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_7"> 17457000 </us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims> | |||||||||||||||||||||
| <us-gaap:NetIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_4_8"> -49732000 </us-gaap:NetIncomeLoss> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="shares" decimals="INF" id="id_123082_08C2C2CC-51D2-4B3B-BD6F-15DF336D63ED_4_0"> 1063900 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_16"> 3546000 </us-gaap:IncreaseDecreaseInAccruedLiabilities> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_08C2C2CC-51D2-4B3B-BD6F-15DF336D63ED_4_1"> 4.33 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <ziop:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2_29"> 71207000 </ziop:ProceedsFromIssuanceOfCommonStockAndWarrantsNet> | |||||||||||||||||||||
| <ziop:ReclassificationOfWarrantLiabilitiesToEquity contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_5603555B-632F-40F5-BF1E-B7E62F61C2F8_6_1"> 265000 </ziop:ReclassificationOfWarrantLiabilitiesToEquity> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_498752x506779" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_1004_0"> 276000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_498752x510320" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_2004_1"> 1038000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x507958" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2002_41"> 8992000 </us-gaap:ConversionOfStockAmountConverted1> | |||||||||||||||||||||
| <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x532266" unitRef="iso4217_USD" decimals="-3" id="id_123082_5603555B-632F-40F5-BF1E-B7E62F61C2F8_4_2"> 12293000 </us-gaap:ProceedsFromWarrantExercises> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x532266_509379x531033" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_2003_600004"> 2259770 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x532266_509379x533570" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_2001_400004"> 2259770 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ReclassificationOfWarrantLiabilitiesToEquity contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x534240" unitRef="iso4217_USD" decimals="-3" id="id_123082_5603555B-632F-40F5-BF1E-B7E62F61C2F8_5_1"> 265000 </ziop:ReclassificationOfWarrantLiabilitiesToEquity> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x534240_509379x531033" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_3003_600005"> 59308 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x534240_509379x533570" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_3001_400005"> 39832 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x534240_509379x586161" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_3002_500005"> 144905 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_508454x506554" unitRef="shares" decimals="INF" id="id_123082_3C6D3E62-61F7-49B6-B9DB-AEB4B5755827_1002_500000"> 4790552 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> | |||||||||||||||||||||
| <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_508454x507958" unitRef="shares" decimals="INF" id="id_123082_3C6D3E62-61F7-49B6-B9DB-AEB4B5755827_2002_500002"> 13252346 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> | |||||||||||||||||||||
| <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_508454x557649" unitRef="shares" decimals="INF" id="id_123082_3C6D3E62-61F7-49B6-B9DB-AEB4B5755827_3002_500001"> 248752 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_509379x531033" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_1003_600006"> 2319078 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_509379x533570" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_1001_400006"> 2299602 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_509379x586161" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_1002_500006"> 144905 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_181_20110630_0_510508x586161" unitRef="iso4217_USD" decimals="-5" id="id_123082_D7DD69C9-B454-427F-BA6E-D9677A8EA770_1003_0"> -9000000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <dei:TradingSymbol contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_71E40D9B-273D-42D3-8940-30A05BBAED18_1_400000"> ZIOP </dei:TradingSymbol> | |||||||||||||||||||||
| <dei:EntityRegistrantName contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_71E40D9B-273D-42D3-8940-30A05BBAED18_1_400001"> ZIOPHARM ONCOLOGY INC </dei:EntityRegistrantName> | |||||||||||||||||||||
| <dei:AmendmentFlag contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_F4C41A08-014D-4CA0-9085-A69074195785_1_1"> false </dei:AmendmentFlag> | |||||||||||||||||||||
| <dei:EntityFilerCategory contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_71E40D9B-273D-42D3-8940-30A05BBAED18_1_400004"> Accelerated Filer </dei:EntityFilerCategory> | |||||||||||||||||||||
| <dei:DocumentFiscalPeriodFocus contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_F4C41A08-014D-4CA0-9085-A69074195785_1_4"> Q2 </dei:DocumentFiscalPeriodFocus> | |||||||||||||||||||||
| <dei:DocumentFiscalYearFocus contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_F4C41A08-014D-4CA0-9085-A69074195785_1_3"> 2012 </dei:DocumentFiscalYearFocus> | |||||||||||||||||||||
| <dei:DocumentType contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_F4C41A08-014D-4CA0-9085-A69074195785_1_0"> 10-Q </dei:DocumentType> | |||||||||||||||||||||
| <dei:DocumentPeriodEndDate contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_F4C41A08-014D-4CA0-9085-A69074195785_1_2"> 2012-06-30 </dei:DocumentPeriodEndDate> | |||||||||||||||||||||
| <dei:EntityCentralIndexKey contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_71E40D9B-273D-42D3-8940-30A05BBAED18_1_400002"> 0001107421 </dei:EntityCentralIndexKey> | |||||||||||||||||||||
| <dei:CurrentFiscalYearEndDate contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_71E40D9B-273D-42D3-8940-30A05BBAED18_1_400003"> --12-31 </dei:CurrentFiscalYearEndDate> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_927AFDF7-3041-4A1F-AD62-57FD133217B2_1_1"> 10320000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue> | |||||||||||||||||||||
| <us-gaap:OperatingIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_5"> -41599000 </us-gaap:OperatingIncomeLoss> | |||||||||||||||||||||
| <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_5"> -6461000 </us-gaap:OtherNoncashIncomeExpense> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_15"> -258000 </us-gaap:IncreaseDecreaseInAccountsPayable> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_6"> -23000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5008_1100002"> 2290000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> | |||||||||||||||||||||
| <us-gaap:ContractsRevenue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_0"> 400000 </us-gaap:ContractsRevenue> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_123082_5A5F1688-5917-4972-9E05-E3C88457EC1F_1_2"> 170302 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingGainsLosses contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_7"> -6461000 </us-gaap:OtherNonoperatingGainsLosses> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_28196DD5-3EB8-4893-BD54-23CE46C23067_1_2"> P7Y2M9D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_4"> 2290000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_12BDD485-E087-448A-968A-4816AF9E7BE3_1_2"> 4.96 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice> | |||||||||||||||||||||
| <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_4"> 41999000 </us-gaap:OperatingCostsAndExpenses> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareDiluted contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_10"> -0.62 </us-gaap:EarningsPerShareDiluted> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_12BDD485-E087-448A-968A-4816AF9E7BE3_1_4"> 5.90 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_123082_688607D2-5409-485C-B6C4-C2CED35501B7_1_3"> 8300 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised> | |||||||||||||||||||||
| <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_42"> 412000 </us-gaap:DebtConversionConvertedInstrumentAmount1> | |||||||||||||||||||||
| <us-gaap:DepreciationAndAmortization contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_3"> 265000 </us-gaap:DepreciationAndAmortization> | |||||||||||||||||||||
| <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_26"> 30000 </us-gaap:ProceedsFromStockOptionsExercised> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_19"> -42625000 </us-gaap:NetCashProvidedByUsedInOperatingActivities> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_23"> -1107000 </us-gaap:NetCashProvidedByUsedInInvestingActivities> | |||||||||||||||||||||
| <us-gaap:IncomeTaxesPaid contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_37"/> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_17"> -400000 </us-gaap:IncreaseDecreaseInDeferredRevenue> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_123082_5A5F1688-5917-4972-9E05-E3C88457EC1F_1_3"> 25000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_12BDD485-E087-448A-968A-4816AF9E7BE3_1_3"> 3.61 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5008_1100008"> 49170000 </us-gaap:StockIssuedDuringPeriodValueNewIssues> | |||||||||||||||||||||
| <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_21"> 1107000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_32"> 5678000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_18"> 172000 </us-gaap:IncreaseDecreaseInOtherDeferredLiability> | |||||||||||||||||||||
| <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_3"> 9750000 </us-gaap:GeneralAndAdministrativeExpense> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_6EDA9770-F1A3-4916-8E46-CFBB07A02E77_1_3"> 5.21 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_11"> 7738000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_6EDA9770-F1A3-4916-8E46-CFBB07A02E77_1_2"> 4.51 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_9E2F3C71-35F6-4F7C-8E4E-73714C1D167F_1_1"> P1Y7M2D </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1> | |||||||||||||||||||||
| <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="0" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_12"> 77067424 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5008_1100003"> 30000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> | |||||||||||||||||||||
| <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_28"> 210000 </us-gaap:ProceedsFromWarrantExercises> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareBasic contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_9"> -0.62 </us-gaap:EarningsPerShareBasic> | |||||||||||||||||||||
| <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_2"> 32249000 </us-gaap:ResearchAndDevelopmentExpense> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_31"> 49410000 </us-gaap:NetCashProvidedByUsedInFinancingActivities> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_123082_688607D2-5409-485C-B6C4-C2CED35501B7_1_4"> 158432 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_6EDA9770-F1A3-4916-8E46-CFBB07A02E77_1_4"> 4.41 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="0" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_11"> 77067424 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_13"> 41000 </us-gaap:IncreaseDecreaseInDepositOtherAssets> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" id="id_123082_28196DD5-3EB8-4893-BD54-23CE46C23067_1_1"> P7Y2M9D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_12"> 53000 </us-gaap:IncreaseDecreaseInOtherNoncurrentAssets> | |||||||||||||||||||||
| <us-gaap:InterestPaid contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_36"/> | |||||||||||||||||||||
| <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5008_1100009"> 3426000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts> | |||||||||||||||||||||
| <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_123082_3C6D3E62-61F7-49B6-B9DB-AEB4B5755827_1_400003"> 17695680 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> | |||||||||||||||||||||
| <us-gaap:NetIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_3_8"> -48083000 </us-gaap:NetIncomeLoss> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInReceivables contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_10"> -79000 </us-gaap:IncreaseDecreaseInReceivables> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_123082_08C2C2CC-51D2-4B3B-BD6F-15DF336D63ED_2_0"> 425400 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="shares" decimals="INF" id="id_123082_5A5F1688-5917-4972-9E05-E3C88457EC1F_1_4"> 66360 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_16"> 4681000 </us-gaap:IncreaseDecreaseInAccruedLiabilities> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_08C2C2CC-51D2-4B3B-BD6F-15DF336D63ED_2_1"> 3.48 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <ziop:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1_29"> 49170000 </ziop:ProceedsFromIssuanceOfCommonStockAndWarrantsNet> | |||||||||||||||||||||
| <ziop:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5008_1100004"> 622000 </ziop:StockIssuedDuringPeriodValueStockWarrantsExercised> | |||||||||||||||||||||
| <ziop:ReclassificationOfWarrantLiabilitiesToEquity contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_5603555B-632F-40F5-BF1E-B7E62F61C2F8_3_1"> 412000 </ziop:ReclassificationOfWarrantLiabilitiesToEquity> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_498752x506779" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_1003_0"> 942000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_498752x510320" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_2003_1"> 1348000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <ziop:CollaborativeArrangementAdditionalUpFrontPaymentToBeReceived contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_499645x535137_588826x603784" unitRef="iso4217_USD" decimals="-5" id="id_123082_39D79516-BBBE-4445-A32A-819A3829F64A_1001_2"> 53500000 </ziop:CollaborativeArrangementAdditionalUpFrontPaymentToBeReceived> | |||||||||||||||||||||
| <ziop:CollaborativeArrangementAdditionalUpFrontPaymentToBeReceived contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_499645x588173_588826x603784" unitRef="iso4217_USD" decimals="-5" id="id_123082_39D79516-BBBE-4445-A32A-819A3829F64A_2001_1"> 32500000 </ziop:CollaborativeArrangementAdditionalUpFrontPaymentToBeReceived> | |||||||||||||||||||||
| <us-gaap:OtherExpenses contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_501050x535531_588826x603798" unitRef="iso4217_USD" decimals="-3" id="id_123082_8BCC84EF-E3BD-481C-9E74-BCB7FF9C176D_3002_0"> 120000 </us-gaap:OtherExpenses> | |||||||||||||||||||||
| <ziop:PercentageOfNetProfit contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_501050x535531_588826x603798" unitRef="pure" decimals="2" id="id_123082_8BCC84EF-E3BD-481C-9E74-BCB7FF9C176D_3002_3"> 0.01 </ziop:PercentageOfNetProfit> | |||||||||||||||||||||
| <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x507958" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2001_41"> 166000 </us-gaap:ConversionOfStockAmountConverted1> | |||||||||||||||||||||
| <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x532266" unitRef="iso4217_USD" decimals="-3" id="id_123082_5603555B-632F-40F5-BF1E-B7E62F61C2F8_1_2"> 210000 </us-gaap:ProceedsFromWarrantExercises> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x532266_509379x531033" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_6003_600001"> 102744 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x532266_509379x533570" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_6001_400001"> 102744 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ReclassificationOfWarrantLiabilitiesToEquity contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x534240" unitRef="iso4217_USD" decimals="-3" id="id_123082_5603555B-632F-40F5-BF1E-B7E62F61C2F8_2_1"> 412000 </ziop:ReclassificationOfWarrantLiabilitiesToEquity> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x534240_509379x531033" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_7003_600002"> 89859 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x534240_509379x533570" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_7001_400002"> 12329 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x534240_509379x586161" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_7002_500002"> 373617 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <us-gaap:NetIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x500343" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5007_1000010"> -48083000 </us-gaap:NetIncomeLoss> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x501348" unitRef="shares" decimals="INF" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5003_600003"> 8300 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x501348" unitRef="shares" decimals="INF" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5003_600006"> 66360 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x501348" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5003_700008"> 11000 </us-gaap:StockIssuedDuringPeriodValueNewIssues> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x501348" unitRef="shares" decimals="INF" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5003_600008"> 10114401 </us-gaap:StockIssuedDuringPeriodSharesNewIssues> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x501348" unitRef="shares" decimals="INF" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5003_600005"> 170302 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures> | |||||||||||||||||||||
| <ziop:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x501348" unitRef="shares" decimals="INF" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5003_600004"> 192603 </ziop:StockIssuedDuringPeriodSharesStockWarrantsExercised> | |||||||||||||||||||||
| <ziop:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x504626" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5006_900004"> -166000 </ziop:StockIssuedDuringPeriodValueStockWarrantsExercised> | |||||||||||||||||||||
| <ziop:AdjustmentsToAdditionalPaidInCapitalWarrantExpired contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x504626" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5006_900007"> 5433000 </ziop:AdjustmentsToAdditionalPaidInCapitalWarrantExpired> | |||||||||||||||||||||
| <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x530731" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5005_800002"> 2290000 </us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x530731" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5005_800008"> 49159000 </us-gaap:StockIssuedDuringPeriodValueNewIssues> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x530731" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5005_800003"> 30000 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> | |||||||||||||||||||||
| <ziop:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x530731" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5005_800004"> 788000 </ziop:StockIssuedDuringPeriodValueStockWarrantsExercised> | |||||||||||||||||||||
| <ziop:AdjustmentsToAdditionalPaidInCapitalWarrantExpired contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x530731" unitRef="iso4217_USD" decimals="-3" id="id_123082_785D3197-531F-4B1D-A4E6-CACCC8BB6F8A_5005_800007"> -5433000 </ziop:AdjustmentsToAdditionalPaidInCapitalWarrantExpired> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x531071" id="id_123082_28196DD5-3EB8-4893-BD54-23CE46C23067_1001_4"> P5Y6M7D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x531072" id="id_123082_28196DD5-3EB8-4893-BD54-23CE46C23067_2001_3"> P5Y3M11D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1> | |||||||||||||||||||||
| <us-gaap:ContractRevenueCost contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507611x603123" unitRef="iso4217_USD" decimals="-5" id="id_123082_0B1F11AA-23C7-41FC-A063-C0C288783307_1001_0"> 10700000 </us-gaap:ContractRevenueCost> | |||||||||||||||||||||
| <us-gaap:OperatingExpenses contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_507611x603123" unitRef="iso4217_USD" decimals="-5" id="id_123082_0B1F11AA-23C7-41FC-A063-C0C288783307_1001_1"> 2500000 </us-gaap:OperatingExpenses> | |||||||||||||||||||||
| <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_508454x506554" unitRef="shares" decimals="INF" id="id_123082_3C6D3E62-61F7-49B6-B9DB-AEB4B5755827_1001_400000"> 5397154 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> | |||||||||||||||||||||
| <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_508454x507958" unitRef="shares" decimals="INF" id="id_123082_3C6D3E62-61F7-49B6-B9DB-AEB4B5755827_2001_400002"> 11268678 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> | |||||||||||||||||||||
| <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_508454x557649" id="id_123082_0D5713C8-0E5E-4BA8-B504-645CEA5A68CC_1001_1"> P1Y9M4D </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1> | |||||||||||||||||||||
| <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_508454x557649" unitRef="shares" decimals="INF" id="id_123082_3C6D3E62-61F7-49B6-B9DB-AEB4B5755827_3001_400001"> 1029848 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_509379x531033" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_5003_600003"> 192603 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_509379x533570" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_5001_400003"> 115073 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_509379x586161" unitRef="shares" decimals="INF" id="id_123082_D8A642DC-3280-4395-98EA-5EF9DF523F62_5002_500003"> 373617 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_510508x586161" unitRef="iso4217_USD" decimals="-5" id="id_123082_D7DD69C9-B454-427F-BA6E-D9677A8EA770_1004_0"> -6400000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_512768x505866" unitRef="shares" decimals="INF" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_1001_1"> 373617 </ziop:ClassOfWarrantOrRightExercisedInPeriod> | |||||||||||||||||||||
| <ziop:ContractTerminationDescription contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603123" id="id_123082_0BFCABA0-6A3A-4F11-95CF-808987EC54F4_1001_0"> Our obligation to pay 50% of net profits or revenue described above with respect to these "retained" products will survive termination of the Channel Agreement. </ziop:ContractTerminationDescription> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603799_588157x537113" unitRef="iso4217_USD" decimals="-5" id="id_123082_5EA3AFB4-6CDB-4D09-A80A-78C56FE9C2A6_3002_4"> 2600000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603802_588157x537113" unitRef="iso4217_USD" decimals="-5" id="id_123082_8EF51F28-81E2-45E0-BC37-3C26952D800E_1002_4"> 1000000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603802_588157x537115" unitRef="iso4217_USD" decimals="-5" id="id_123082_8EF51F28-81E2-45E0-BC37-3C26952D800E_3002_2"> 400000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603802_588157x537116" unitRef="iso4217_USD" decimals="-5" id="id_123082_8EF51F28-81E2-45E0-BC37-3C26952D800E_4002_3"> 700000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <us-gaap:ProceedsFromLicenseFeesReceived contextRef="eol_PE83398---1210-Q0004_STD_182_20120630_0_588826x603784" unitRef="iso4217_USD" decimals="-5" id="id_123082_39D79516-BBBE-4445-A32A-819A3829F64A_3001_0"> 5000000 </us-gaap:ProceedsFromLicenseFeesReceived> | |||||||||||||||||||||
| <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE83398---1210-Q0004_STD_25_20120125_0_507611x603123" unitRef="iso4217_USD" decimals="0" id="id_123082_E216D38D-3BAA-48B3-A7F2-D4059BE10A64_1001_0"> 1923075 </us-gaap:ProceedsFromIssuanceOfCommonStock> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE83398---1210-Q0004_STD_25_20120125_0_508454x534907" unitRef="shares" decimals="INF" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_1002_6"> 9650000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_28_20100316_0_553597x603794_588157x537109" unitRef="iso4217_USD" decimals="-3" id="id_123082_403F8303-BB34-47EC-BCEB-EE495E65A537_4003_5"> 100000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <us-gaap:RestructuringCharges contextRef="eol_PE83398---1210-Q0004_STD_30_20120716_0_506663x511390_510660x512888" unitRef="iso4217_USD" decimals="-5" id="id_123082_3F50C244-7266-414C-9ABE-2281A8152E8B_1001_0"> 1100000 </us-gaap:RestructuringCharges> | |||||||||||||||||||||
| <us-gaap:LicenseCosts contextRef="eol_PE83398---1210-Q0004_STD_30_20041015_0_499645x560796_553597x603794" unitRef="iso4217_USD" decimals="-3" id="id_123082_B2D03BBA-E706-4E97-8BB2-336D77F03FE1_1001_0"> 50000 </us-gaap:LicenseCosts> | |||||||||||||||||||||
| <ziop:NumberOfProducts contextRef="eol_PE83398---1210-Q0004_STD_31_20040824_0_553597x603793" unitRef="Patent" decimals="INF" id="id_123082_D733C63C-57E9-41DD-A206-9DFE4B7F5FC8_1001_0"> 2 </ziop:NumberOfProducts> | |||||||||||||||||||||
| <us-gaap:CostOfServicesLicensesAndMaintenanceAgreements contextRef="eol_PE83398---1210-Q0004_STD_31_20061103_0_553597x603797" unitRef="iso4217_USD" decimals="-3" id="id_123082_22A73969-B48A-425B-8537-C6363641173C_1001_4"> 15000 </us-gaap:CostOfServicesLicensesAndMaintenanceAgreements> | |||||||||||||||||||||
| <invest:InvestmentWarrantsExpirationDate contextRef="eol_PE83398---1210-Q0004_STD_31_20070223_0" id="id_123082_02A7207C-06A9-47CF-BE9B-0CBAF0BD0989_1_1"> 2012-02-23 </invest:InvestmentWarrantsExpirationDate> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightIssuedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_31_20070223_0" unitRef="shares" decimals="INF" id="id_123082_02A7207C-06A9-47CF-BE9B-0CBAF0BD0989_1_0"> 1359317 </ziop:ClassOfWarrantOrRightIssuedInPeriod> | |||||||||||||||||||||
| <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE83398---1210-Q0004_STD_31_20120131_0_508454x534907" unitRef="iso4217_USD" decimals="-5" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_1003_8"> 49200000 </us-gaap:ProceedsFromIssuanceOfCommonStock> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE83398---1210-Q0004_STD_31_20120131_0_508454x534907" unitRef="shares" decimals="INF" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_1003_6"> 464401 </us-gaap:StockIssuedDuringPeriodSharesNewIssues> | |||||||||||||||||||||
| <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE83398---1210-Q0004_STD_31_20120131_0_508454x534907_547800x569860" unitRef="shares" decimals="INF" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_2003_7"> 10114401 </us-gaap:StockIssuedDuringPeriodSharesNewIssues> | |||||||||||||||||||||
| <ziop:ConsultingFees contextRef="eol_PE83398---1210-Q0004_STD_31_20080408_0_501050x535531_512812x516640_588826x603798" unitRef="iso4217_USD" decimals="-3" id="id_123082_8BCC84EF-E3BD-481C-9E74-BCB7FF9C176D_1001_2"> 500000 </ziop:ConsultingFees> | |||||||||||||||||||||
| <ziop:ConsultingFees contextRef="eol_PE83398---1210-Q0004_STD_31_20080408_0_501050x535531_575210x533711_588826x603798" unitRef="iso4217_USD" decimals="-3" id="id_123082_8BCC84EF-E3BD-481C-9E74-BCB7FF9C176D_2001_1"> 20000 </ziop:ConsultingFees> | |||||||||||||||||||||
| <invest:InvestmentWarrantsExpirationDate contextRef="eol_PE83398---1210-Q0004_STD_31_20050531_0" id="id_123082_02A7207C-06A9-47CF-BE9B-0CBAF0BD0989_2_1"> 2012-05-31 </invest:InvestmentWarrantsExpirationDate> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightIssuedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_31_20050531_0" unitRef="shares" decimals="INF" id="id_123082_02A7207C-06A9-47CF-BE9B-0CBAF0BD0989_2_0"> 579 </ziop:ClassOfWarrantOrRightIssuedInPeriod> | |||||||||||||||||||||
| <ziop:IssuanceOfWarrantsValue contextRef="eol_PE83398---1210-Q0004_STD_31_20050531_0_512768x505866" unitRef="iso4217_USD" decimals="-5" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_1003_3"> 1600000 </ziop:IssuanceOfWarrantsValue> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightIssuedInPeriod contextRef="eol_PE83398---1210-Q0004_STD_31_20050531_0_512768x505866" unitRef="shares" decimals="INF" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_1003_0"> 419786 </ziop:ClassOfWarrantOrRightIssuedInPeriod> | |||||||||||||||||||||
| <ziop:PercentageOfRevenue contextRef="eol_PE83398---1210-Q0004_STD_31_20110106_0_553597x603123_575210x533712" unitRef="pure" decimals="2" id="id_123082_6DC7714E-A9BA-4211-9D78-E7BF6647685B_1001_1"> 0.50 </ziop:PercentageOfRevenue> | |||||||||||||||||||||
| <ziop:PercentageOfNetProfit contextRef="eol_PE83398---1210-Q0004_STD_31_20110106_0_553597x603123_575210x533712" unitRef="pure" decimals="2" id="id_123082_6DC7714E-A9BA-4211-9D78-E7BF6647685B_1001_0"> 0.50 </ziop:PercentageOfNetProfit> | |||||||||||||||||||||
| <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_1A6C9452-1D9D-4173-A662-D241965E4CEF_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>8. Warrants</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company has issued both warrants that are accounted for as liabilities and warrants that are accounted for as equity instruments. The number of warrants outstanding at June 30, 2012 and December 31, 2011 were as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2">June 30,</td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2">December 31,</td> <td> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 54%">Liability-classified warrants</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 20%">8,050,709</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 20%">8,424,905</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Equity-classified warrants</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,217,969</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,692,359</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total warrants</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 11,268,678</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 13,117,264</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Liability-Classified Warrants</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In May 2005, the Company issued 419,786 warrants to placement agents for services performed in connection with a 2005 private placement (the “2005 Warrants”) which were originally valued at $1.6 million. Subject to certain exceptions, the 2005 Warrants provide for anti-dilution protection should common stock or common stock equivalents be subsequently issued at a price less than the exercise price of the 2005 Warrants then in effect, which was initially $4.75 per share. This provision was triggered when the Company sold stock in a 2006 private placement at $4.63 per share. Accordingly, the 2005 Warrants were re-priced at $4.69. The provision was triggered a second time upon completion of a 2009 private placement in which the Company sold stock at $1.825 per share and issued common stock purchase warrants with an exercise price of $2.04, and the 2005 Warrants were re-priced at $4.25. The provision was triggered again when the Company sold stock in a December 2009 public offering at $3.10 per share and the 2005 Warrants were re-priced at $3.93. During the first six months of 2012, 373,617 warrants were exercised and 579 expired on May 31, 2012.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Also, in connection with its December 2009 public securities offering, the Company issued warrants to purchase an aggregate of 8,206,520 shares of common stock (including the investor warrants and 464,520 warrants issued to the underwriters for the offering) (the “2009 Warrants”). The 2009 Warrants issued to investors were exercisable immediately and the warrants issued to underwriters became exercisable six months after the date of issuance. The 2009 Warrants have an exercise price of $4.02 per share and have a five-year term. The fair value of the 2009 Warrants was estimated at $22.9 million using a Black-Scholes model with the following assumptions: expected volatility of 105%, risk free interest rate of 2.14%, expected life of five years and no dividends.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company assessed whether the 2005 Warrants and the 2009 Warrants require accounting as derivatives. The Company determined that these warrants were not indexed to the Company’s own stock in accordance with accounting standards codification Topic 815, <i>Derivatives and Hedging</i>. As such, the Company has concluded these warrants did not meet the scope exception for determining whether the instruments require accounting as derivatives and were classified as liabilities.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In December 2011, the Company changed from using a Black-Scholes pricing model to estimate the value of the liability-classified warrants to a Binomial/Monte Carlo pricing model. The following assumptions were used in the Binomial/Monte Carlo valuation model at June 30, 2012 and the Black-Scholes valuation model at June 30, 2011:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">June 30, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 64%">Risk-free interest rate</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.37</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.18 - 1.01</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected life in years</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2.44</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.92 - 3.43</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected volatility</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">70</td> <td style="TEXT-ALIGN: left">%</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">45 - 97</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected dividend yield</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Steps per year</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">12</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">N/A</td> <td style="TEXT-ALIGN: left"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The change in the fair value of the warrant liability resulted in losses of $0.6 million and $6.4 million for the three and six months ended June 30, 2012, respectively. The change in the fair value of the warrant liability resulted in a gain of $2.1 million for the three months ended June 30, 2011 and a loss of $9.0 million for the six months ended June 30, 2011. The change in the fair value of the warrant liability was charged to other income (expense) in the Statements of Operations.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">During the first six months of 2012, warrant exercises were as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Common</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Liability</td> <td style="FONT-WEIGHT: bold"> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Equity</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Liability</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Stock</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Reclassed</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Cash</td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic"> (in thousands, except share data)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Issued</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">to Equity</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Received</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 25%">Cash exercises</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">102,744</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">102,744</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">210</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Cashless exercises</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 12,329</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 373,617</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 89,859</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 412</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 115,073</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 373,617</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 192,603</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 412</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 210</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">During the first six months of 2011, warrant exercises were as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Common</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Liability</td> <td style="FONT-WEIGHT: bold"> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Equity</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Liability</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Stock</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Reclassed</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Cash</td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic"> (in thousands, except share data)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Issued</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">to Equity</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Received</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 25%">Cash exercises</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">2,259,770</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">2,259,770</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">12,293</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Cashless exercises</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 39,832</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 144,905</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 59,308</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 265</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,299,602</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 144,905</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,319,078</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 265</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 12,293</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">During the six months ended June 30, 2012, 1,359,317 warrants issued on February 23, 2007, exercisable at $5.75, expired unexercised on February 23, 2012 and 579 warrants issued on May 31, 2005, exercisable at $3.93, expired unexercised on May 31, 2012.</p> </div> </us-gaap:StockholdersEquityNoteDisclosureTextBlock> | |||||||||||||||||||||
| <us-gaap:OperatingIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_5_5"> -238626000 </us-gaap:OperatingIncomeLoss> | |||||||||||||||||||||
| <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_5"> -1740000 </us-gaap:OtherNoncashIncomeExpense> | |||||||||||||||||||||
| <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_8A0EE38D-0A25-412F-AB86-C89593B6BAC0_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>3. Collaborations and Alliances</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K.K. (“Solasia”).</p> <p style="TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Pursuant to the License and Collaboration Agreement (the “Agreement”), the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use in a pan-Asian/Pacific territory comprised of Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">As consideration for the license, the Company received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory, and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. The Company will also be entitled to receive double digit royalty payments from Solasia based upon net sales of licensed products in the applicable territories, once commercialized, and a percentage of sublicense revenues generated by Solasia. </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The upfront payment for research and development funding is earned over the period of effort. The Company currently estimates this period to be 75 months, which could be adjusted in the future.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Under the Agreement, the Company provides Solasia with drug product to conduct clinical trials. These transfers are accounted for as a reduction of research and development costs and an increase in collaboration receivables.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Agreement provides that Solasia will be responsible for the development and commercialization of darinaparsin in the pan-Asian/Pacific territory.</p> </div> </us-gaap:CollaborativeArrangementDisclosureTextBlock> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_15"> 1469000 </us-gaap:IncreaseDecreaseInAccountsPayable> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_5_6"> 4691000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <us-gaap:ContractsRevenue contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_5_0"> 1067000 </us-gaap:ContractsRevenue> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingGainsLosses contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_5_7"> -1740000 </us-gaap:OtherNonoperatingGainsLosses> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_847A5D03-579F-453D-9BC2-872D614E0A3E_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>5. Net Loss per Share</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company's potential dilutive shares, which include outstanding common stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be antidilutive. Such potential shares of common stock at June 30, 2012 and 2011 consist of the following:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="6"> For the Six Months</td> <td> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6">Ended June 30,</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 64%">Stock options</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">5,397,154</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">4,790,552</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Unvested restricted common stock</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">1,029,848</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">248,752</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Warrants</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 11,268,678</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 13,252,346</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 17,695,680</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 18,291,650</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div> </us-gaap:EarningsPerShareTextBlock> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_4"> 17591000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_5_4"> 239693000 </us-gaap:OperatingCostsAndExpenses> | |||||||||||||||||||||
| <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_22"> 1000 </us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment> | |||||||||||||||||||||
| <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_8596E762-E144-4EDC-AAAA-B8D41AC111F4_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>4. Fair Value Measurements</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company accounts for fair value measurements of its financial assets and liabilities and non-financial assets and non-financial liabilities, except those that are recognized or disclosed in the financial statements at fair value on a recurring basis. The accounting standard defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td><font style="FONT-SIZE: 10pt">Level 1 - Quoted prices in active markets for identical assets or liabilities.</font></td> </tr> </table> <p style="TEXT-INDENT: 1.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td><font style="FONT-SIZE: 10pt">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></td> </tr> </table> <p style="TEXT-INDENT: 1.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td><font style="FONT-SIZE: 10pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td> </tr> </table> <p style="TEXT-INDENT: 1.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Assets and liabilities measured at fair value on a recurring basis as of June 30, 2012 and December 31, 2011 are as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic" nowrap="nowrap"> ($ in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="10" nowrap="nowrap"> Fair Value Measurements at Reporting Date Using</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid" nowrap="nowrap"> Description</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance as of<br /> June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Quoted Prices in<br /> Active Markets for<br /> Identical<br /> Assets/Liabilities<br /> (Level 1)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Significant Other<br /> Observable Inputs<br /> (Level 2)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Significant<br /> Unobservable Inputs<br /> (Level 3)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 40%"> Cash equivalents</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 109,455</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 109,455</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Warrant liability</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 25,472</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 25,472</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic" nowrap="nowrap"> ($ in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="10" nowrap="nowrap"> Fair Value Measurements at Reporting Date Using</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid" nowrap="nowrap"> Description</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance as of<br /> December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Quoted Prices in<br /> Active Markets for<br /> Identical<br /> Assets/Liabilities<br /> (Level 1)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Significant Other<br /> Observable Inputs<br /> (Level 2)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Significant<br /> Unobservable<br /> Inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 40%"> Cash equivalents</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 103,736</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 103,736</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Warrant liability</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 19,425</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 19,425</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The cash equivalents represent deposits in a short term U.S. treasury money market mutual fund quoted in an active market and classified as a Level I asset. The Company’s Level II financial liabilities consist of long-term investor and placement agent warrants issued in connection with its December 2009 public offering. The warrants were valued using Binomial/Monte Carlo valuation models. See Note 8 for additional disclosures on the valuation methodology and significant assumptions.</p> </div> </us-gaap:FairValueDisclosuresTextBlock> | |||||||||||||||||||||
| <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_42"> 764000 </us-gaap:DebtConversionConvertedInstrumentAmount1> | |||||||||||||||||||||
| <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_27"> 2321000 </us-gaap:PaymentsForRepurchaseOfCommonStock> | |||||||||||||||||||||
| <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_1DC883F7-08D3-421B-BF0A-9E504C3AC42E_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>6. Related Party Transactions</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On January 6, 2011, the Company entered into an Exclusive Channel Partner Agreement (the “Channel Agreement”) with Intrexon Corporation (see Note 7 for additional disclosure relating to the Channel Agreement). During the six months ended June 30, 2012, the Company paid Intrexon approximately $10.7 million, of which $2.5 million was for services already incurred and the remaining $8.2 million expected to be incurred within a year. This amount has been included as part of prepaid expenses and other current assets on the accompanying balance sheet as of June 30, 2012. The Company does not owe any amounts to Intrexon that have not already been accrued for as of June 30, 2012.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On January 25, 2012, Intrexon purchased 1,923,075 shares of common stock in the Company’s public offering (see Note 9).</p> </div> </us-gaap:RelatedPartyTransactionsDisclosureTextBlock> | |||||||||||||||||||||
| <us-gaap:DepreciationAndAmortization contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_3"> 2181000 </us-gaap:DepreciationAndAmortization> | |||||||||||||||||||||
| <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_26"> 1373000 </us-gaap:ProceedsFromStockOptionsExercised> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_19"> -185433000 </us-gaap:NetCashProvidedByUsedInOperatingActivities> | |||||||||||||||||||||
| <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_A2F8B2EA-4F1C-4124-B765-8858DA528635_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">A summary of the status of unvested restricted stock for the six months ended June 30, 2012 is as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted-Average<br /> Grant Date Fair Value</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 64%">Non-vested, December 31, 2011</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">950,906</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">4.34</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">170,302</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">4.51</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Vested</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(25,000</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">5.21</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Cancelled</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (66,360</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4.41</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Non-vested, June 30, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,029,848</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.34</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div> </us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_23"> -4173000 </us-gaap:NetCashProvidedByUsedInInvestingActivities> | |||||||||||||||||||||
| <us-gaap:IncomeTaxesPaid contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_37"/> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_17"> 3933000 </us-gaap:IncreaseDecreaseInDeferredRevenue> | |||||||||||||||||||||
| <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_21"> 4174000 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> | |||||||||||||||||||||
| <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_32"> 110391000 </us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_18"> 367000 </us-gaap:IncreaseDecreaseInOtherDeferredLiability> | |||||||||||||||||||||
| <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_5_3"> 78545000 </us-gaap:GeneralAndAdministrativeExpense> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_11"> 9051000 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> | |||||||||||||||||||||
| <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_20BDA9FA-A9F6-49A8-B96E-F1FBB6786175_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Stock option activity under the Company’s stock option plan for the six months ended June 30, 2012 is as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic" nowrap="nowrap"> (in thousands, except share and per share data)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of<br /> Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted-<br /> Average Exercise<br /> Price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted-<br /> Average<br /> Contractual<br /> Term (Years)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Aggregate<br /> Intrinsic Value</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 40%">Outstanding, December 31, 2011</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">5,138,486</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">4.08</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">425,400</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">4.96</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Exercised</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(8,300</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">3.61</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Cancelled</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (158,432</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5.90</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Outstanding, June 30, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,397,154</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.10</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7.19</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10,320</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Vested and unvested expected to vest at June 30, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,340,550</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.10</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7.19</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10,212</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Options exercisable, June 30, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,124,387</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.40</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.28</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 8,137</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Options exercisable, December 31, 2011</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,911,186</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.21</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.52</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,232</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Options available for future grant</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,678,000</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div> </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock> | |||||||||||||||||||||
| <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_E5111800-43A1-4999-9A72-C7C409BDE134_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>1. Business</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Overview</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> ZIOPHARM Oncology, Inc. (“ZIOPHARM” or the “Company”) is a biopharmaceutical company that seeks to acquire, develop and commercialize, on its own or with other commercial partners, products for the treatment of important unmet medical needs in cancer.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company’s operations to date have consisted primarily of raising capital and conducting research and development. Accordingly, the Company is considered to be in the development stage at June 30, 2012. The Company's fiscal year ends on December 31.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company has operated at a loss since its inception in 2003 and has minimal revenues. The Company anticipates that losses will continue for the foreseeable future. At June 30, 2012, the Company’s accumulated deficit was approximately $235.7 million. The Company currently believes that it has sufficient capital to fund development and commercialization activities into the second half of 2013. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Basis of Presentation</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and note disclosures required by generally accepted accounting principles in the United States have been condensed or omitted pursuant to such rules and regulations.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">It is management’s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2011 included in the Company’s Form 10-K for such fiscal year.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The year-end balance sheet data was derived from the audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The results disclosed in the Statements of Operations for the three and six months ended June 30, 2012 are not necessarily indicative of the results to be expected for the full fiscal year.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><i>Use of Estimates</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. <font style="FONT-FAMILY: Times New Roman, Times, Serif">Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</font></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company’s most significant estimates and judgments used in the preparation of its financial statements are:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td>Clinical trial expenses;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td>Fair value measurements for stock based compensation and warrants; and</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td>Income taxes.</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Subsequent Events</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. Except as disclosed below, the Company did not have any other material subsequent events that impacted its financial statements or disclosures.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On July 16, 2012, the Company announced that it has restructured its management team and will also be closing its Germantown, MD office. As a result of this action, the Company expects to record a restructuring charge, consisting primarily of severance and health benefit continuation costs, of approximately $1.1 million in the third quarter of 2012.</p> </div> </us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock> | |||||||||||||||||||||
| <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_28"> 12959000 </us-gaap:ProceedsFromWarrantExercises> | |||||||||||||||||||||
| <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_5_2"> 161148000 </us-gaap:ResearchAndDevelopmentExpense> | |||||||||||||||||||||
| <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_31"> 299997000 </us-gaap:NetCashProvidedByUsedInFinancingActivities> | |||||||||||||||||||||
| <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_CD396B41-362E-44C1-8382-F3967068CFC6_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company's potential dilutive shares, which include outstanding common stock options, unvested restricted stock and warrants, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be antidilutive. Such potential shares of common stock at June 30, 2012 and 2011 consist of the following:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 60%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="6"> For the Six Months</td> <td> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6">Ended June 30,</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 64%">Stock options</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">5,397,154</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">4,790,552</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Unvested restricted common stock</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">1,029,848</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">248,752</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Warrants</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 11,268,678</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 13,252,346</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 17,695,680</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 18,291,650</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div> </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock> | |||||||||||||||||||||
| <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_6FBA68BF-58FE-431F-AE8D-3D19D24C5738_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The number of warrants outstanding at June 30, 2012 and December 31, 2011 were as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2">June 30,</td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2">December 31,</td> <td> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 54%">Liability-classified warrants</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 20%">8,050,709</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 20%">8,424,905</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Equity-classified warrants</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,217,969</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,692,359</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total warrants</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 11,268,678</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 13,117,264</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div> </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock> | |||||||||||||||||||||
| <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_A60EE41B-EC0B-4395-A5B8-FC556F452B62_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Assets and liabilities measured at fair value on a recurring basis as of June 30, 2012 and December 31, 2011 are as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic" nowrap="nowrap"> ($ in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="10" nowrap="nowrap"> Fair Value Measurements at Reporting Date Using</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid" nowrap="nowrap"> Description</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance as of<br /> June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Quoted Prices in<br /> Active Markets for<br /> Identical<br /> Assets/Liabilities<br /> (Level 1)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Significant Other<br /> Observable Inputs<br /> (Level 2)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Significant<br /> Unobservable Inputs<br /> (Level 3)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 40%"> Cash equivalents</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 109,455</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 109,455</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Warrant liability</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 25,472</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 25,472</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic" nowrap="nowrap"> ($ in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="10" nowrap="nowrap"> Fair Value Measurements at Reporting Date Using</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid" nowrap="nowrap"> Description</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance as of<br /> December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Quoted Prices in<br /> Active Markets for<br /> Identical<br /> Assets/Liabilities<br /> (Level 1)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Significant Other<br /> Observable Inputs<br /> (Level 2)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Significant<br /> Unobservable<br /> Inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> <td> </td> <td style="TEXT-ALIGN: center" colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 40%"> Cash equivalents</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 103,736</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 103,736</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Warrant liability</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 19,425</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 19,425</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div> </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock> | |||||||||||||||||||||
| <us-gaap:ProceedsFromContributedCapital contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_25"> 500000 </us-gaap:ProceedsFromContributedCapital> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInDepositOtherAssets contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_13"> 132000 </us-gaap:IncreaseDecreaseInDepositOtherAssets> | |||||||||||||||||||||
| <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_6"> -9000 </us-gaap:GainLossOnSaleOfPropertyPlantEquipment> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_12"> 824000 </us-gaap:IncreaseDecreaseInOtherNoncurrentAssets> | |||||||||||||||||||||
| <us-gaap:InterestPaid contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_36"/> | |||||||||||||||||||||
| <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_96AC1C27-1D46-462F-AAF2-151B625A9392_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>7. Commitments and Contingencies</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Patent and Technology License Agreement—The University of Texas M. D. Anderson Cancer Center and the Texas A&M University System.</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On August 24, 2004, the Company entered into a patent and technology license agreement with The Board of Regents of the University of Texas System, acting on behalf of The University of Texas M. D. Anderson Cancer Center and the Texas A&M University System (collectively, the “Licensors”). Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">As partial consideration for the license rights obtained, the Company made an upfront payment in 2004 of $125 thousand and granted the Licensors 250,487 shares of the Company’s common stock. In addition, the Company issued options to purchase an additional 50,222 shares outside the 2003 Stock Option Plan for $0.002 per share following the successful completion of certain clinical milestones, which vested with respect to 12,555 shares upon the filing of an Investigation New Drug application (“IND”) for darinaparsin in 2005 and vested with respect to another 25,111 shares upon the completion of dosing of the last patient for both Phase 1 clinical trials in 2007. The Company recorded $120 thousand of stock based compensation expense related to the vesting in 2007. The remaining 12,556 shares will vest upon enrollment of the first patient in a multi-center pivotal clinical trial i.e. a human clinical trial intended to provide the substantial evidence of efficacy necessary to support the filing of an approvable New Drug Application (“NDA”). In addition, the Licensors are entitled to receive certain milestone payments, including $100 thousand that was paid in 2005 upon the commencement of Phase 1 clinical trial and $250 thousand that was paid in 2006 upon the dosing of the first patient in the Company-sponsored Phase 2 clinical trial for darinaparsin. The Company may be required to make additional payments upon achievement of certain other milestones in varying amounts which on a cumulative basis could total up to an additional $4.5 million. In addition, the Licensors are entitled to receive single-digit percentage royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. In addition, the Company also paid the Licensors $100 thousand in 2006 and 2007 to conduct scientific research with the Company obtaining exclusive right to all resulting intellectual property rights. The sponsored research agreements governing this research and any related extensions expired in February 2008 with no payments being made subsequent to that date.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The license agreement also contains other provisions customary and common in similar agreements within the industry, such as the right to sublicense the Company rights under the agreement. However, if the Company sublicenses its rights prior to the commencement of a pivotal study, i.e. a human clinical trial intended to provide the substantial evidence of efficacy necessary to support the filing of an approvable NDA, the Licensors will be entitled to receive a share of the payments received by the Company in exchange for the sublicense (subject to certain exceptions). The term of the license agreement extends until the expiration of all claims under patents and patent applications associated with the licensed technology, subject to earlier termination in the event of defaults by the Company or the Licensors under the license agreement, or if the Company becomes bankrupt or insolvent. No milestones under the license agreement were reached or expensed during the years ended December 31, 2009, 2010, 2011 or for the six months ended June 30, 2012.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>License Agreement with DEKK-Tec, Inc.</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On October 15, 2004, the Company entered into a license agreement with DEKK-Tec, Inc., pursuant to which it was granted an exclusive, worldwide license for palifosfamide. As part of the signing of license agreement with DEKK-Tec, the Company expensed an upfront $50 thousand payment to DEKK-Tec in 2004.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In consideration for the license rights, DEKK-Tec is entitled to receive payments upon achieving certain milestones in varying amounts, which on a cumulative basis may total $4.0 million. Of the aggregate milestone payments, most will be creditable against future royalty payments as referenced below. The Company expensed a $100 thousand milestone payment upon achieving Phase 2 milestones during the year ended December 31, 2006. Additionally, in 2004 the Company issued DEKK-Tec an option to purchase 27,616 shares of the Company’s common stock for $0.02 per share. Upon the execution of the license agreement, 6,904 shares vested and were subsequently exercised in 2005 and the remaining options will vest upon certain milestone events, culminating with final FDA approval of the first NDA submitted by the Company (or by its sublicensee) for palifosfamide. DEKK-Tec is entitled to receive single-digit percentage royalty payments on the sales of palifosfamide should it be approved for commercial sale. On March 16, 2010, the Company expensed a $100 thousand milestone payment upon receiving a United States Patent for palifosfamide. In December 2010, the Company expensed a $300 thousand milestone payment and vested 6,904 stock options upon achieving Phase 3 milestones. These options were subsequently exercised in 2011. The Company’s obligation to pay royalties will terminate on a country-by-country basis upon the expiration of all valid claims of patents in such country covering licensed product, subject to earlier termination in the event of defaults by the parties under the license agreement. No milestones under the license agreement were reached or expensed during the years ended December 31, 2009, 2011 or for the six months ended June 30, 2012.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Option Agreement with Southern Research Institute (“SRI”)</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On December 22, 2004, the Company entered into an Option Agreement with SRI (the “Option Agreement”), pursuant to which the Company was granted an exclusive option to obtain an exclusive license to SRI’s interest in certain intellectual property, including exclusive rights related to certain isophosphoramide mustard analogs.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Also on December 22, 2004, the Company entered into a Research Agreement with SRI pursuant to which the Company agreed to spend a sum not to exceed $200 thousand between the execution of the agreement and December 21, 2006, including a $25 thousand payment that was made simultaneously with the execution of the agreement, to fund research and development work by SRI in the field of isophosphoramide mustard analogs. The Option Agreement was exercised on February 13, 2007. Under the license agreement entered into upon exercise of the option, the Company is required to remit minimum annual royalty payments of $25 thousand until the first commercial sale of a licensed product. These payments were made for the years ended December 31, 2008, 2009, 2010 and 2011. The Company may be required to make payments upon achievement of certain milestones in varying amounts which on a cumulative basis could total up to $775,000. In addition, SRI will be entitled to receive single digit percentage royalty payments on the sales of a licensed product in any country until all licensed patents rights in that country which are utilized in the product have expired. No milestones under the license agreement were reached or expensed during the years ended December 31, 2009, 2010, 2011 or for the six months ended June 30, 2012.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>License Agreement with Baxter Healthcare Corporation</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On November 3, 2006, the Company entered into a definitive Asset Purchase Agreement for indibulin and a License Agreement to proprietary nanosuspension technology with affiliates of Baxter Healthcare S.A. The purchase included the entire indibulin intellectual property portfolio as well as existing drug substance and capsule inventories. The terms of the Asset Purchase Agreement included an upfront cash payment of approximately $1.1 million and an additional $100 thousand payment for existing inventory, both of which were expensed in 2006. In addition to the upfront costs, the Asset Purchase Agreement includes additional diligence and milestone payments that could amount to approximately $8 million in the aggregate and royalties on net sales of products covered by a valid claim of a patent for the life of the patent on a country-by-country basis. The Company expensed a $625 thousand milestone payment upon the successful U.S. IND application for indibulin in 2007. The License Agreement requires payment of a $15 thousand annual patent and license prosecution/maintenance fee through the expiration of the last of the licensed patents, which is expected to expire in 2025, and single-digit royalties on net sales of licensed products covered by a valid claim of a patent for the life of the patent on a country-by-country basis. The term of the license agreement extends until the expiration of the last to expire of the patents covering the licensed products, subject to earlier termination in the event of defaults by the parties under the license agreement.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">In October 2009, the Baxter License Agreement was amended to allow the Company to manufacturer indibulin. No milestones under the license agreement were reached or expensed during the years ended December 31, 2009, 2010, 2011 or for the six months ended June 30, 2012.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Exclusive Channel Partner Agreement with Intrexon Corporation</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On January 6, 2011, we entered into the Channel Agreement, with Intrexon that governs a “channel partnering” arrangement in which we use Intrexon’s technology directed towards <i>in vivo</i> expression of effectors in connection with the development of ZIN-CTI-001 and ZIN-ATI-001 and generally to research, develop and commercialize products, in each case in which DNA is administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which we collectively refer to as the Cancer Program. The Channel Agreement establishes committees comprised of representatives of us and Intrexon that govern activities related to the Cancer Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Channel Agreement grants us a worldwide license to use patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving DNA administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer (collectively the “ZIOPHARM Products”). Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of ZIOPHARM Products, and otherwise is non-exclusive. Subject to limited exceptions, we may not sublicense the rights described without Intrexon’s written consent.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Under the Channel Agreement, and subject to certain exceptions, we are responsible for, among other things, the performance of the Cancer Program, including development, commercialization and certain aspects of manufacturing of ZIOPHARM Products. Intrexon is responsible for the costs of establishing manufacturing capabilities and facilities for the bulk manufacture of products developed under the Cancer Program, certain other aspects of manufacturing and costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Intrexon’s patents.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Subject to certain expense allocations and other offsets provided in the Channel Agreement, we will pay Intrexon on a quarterly basis 50% of net profits derived in that quarter from the sale of ZIOPHARM Products, calculated on a ZIOPHARM Product-by- ZIOPHARM Product basis. We have likewise agreed to pay Intrexon on a quarterly basis 50% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement. In addition, in partial consideration for each party’s execution and delivery of the Channel Agreement, we entered into a Stock Purchase Agreement with Intrexon.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">During the first 24 months of the agreement, either we or Intrexon may terminate the Channel Agreement in the event of a material breach by the other and Intrexon may terminate the Channel Agreement under certain circumstances if we assign our rights under the Channel Agreement without Intrexon’s consent. Following the first 24 months of the agreement, Intrexon may also terminate the Channel Agreement if we fail to use diligent efforts to develop and commercialize ZIOPHARM Products or if we elect not to pursue the development of a Cancer Program identified by Intrexon that is a “Superior Therapy” as defined in the Channel Agreement. Also following the first 24 months of the agreement, we may voluntarily terminate the Channel Agreement upon 90 days written notice to Intrexon.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Upon termination of the Channel Agreement, we may continue to develop and commercialize any ZIOPHARM Product that, at the time of termination:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td>is being commercialized by us<font style="FONT-FAMILY: Times New Roman, Times, Serif">;</font></td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td>has received regulatory approval<font style="FONT-FAMILY: Times New Roman, Times, Serif">;</font></td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td>is a subject of an application for regulatory approval that is pending before the applicable regulatory authority<font style="FONT-FAMILY: Times New Roman, Times, Serif">; or</font></td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"><font style="FONT-FAMILY: Symbol">·</font></td> <td>is the subject of at least an ongoing Phase 2 clinical trial (in the case of a termination by Intrexon due to an uncured breach or a voluntary termination by us), or an ongoing Phase 1 clinical trial in the field (in the case of a termination by us due to an uncured breach or a termination by Intrexon following an unconsented assignment by us or our election not to pursue development of a Superior Therapy).</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Our obligation to pay 50% of net profits or revenue described above with respect to these “retained” products will survive termination of the Channel Agreement.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Collaboration Agreement with Harmon Hill, LLC</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On April 8, 2008, the Company signed a collaboration agreement for Harmon Hill, LLC (“Harmon Hill”) to provide consulting and other services for the development and commercialization of oncology therapeutics by ZIOPHARM. Under the agreement the Company has agreed to pay Harmon Hill $20 thousand per month for the consulting services and has further agreed to pay Harmon Hill (a) $500 thousand upon the first patient dosing of the Specified Drug in a pivotal trial, which trial uses a dosing regime introduced by Harmon Hill; and (b) provided that the Specified Drug receives regulatory approval from the FDA, the European Medicines Agency or another regulatory agency for the marketing of the Specified Drug, a 1% royalty of the Company’s net sales will be awarded to Harmon Hill. If the Specified Drug is sublicensed to a third party, the agreement entitles Harmon Hill to 1% award of royalties or other payments received from a sublicense. The agreement expired on May 8, 2012 and is currently being renegotiated through November 8, 2012. The Company expensed $240 thousand during each of the years ended December 31, 2009, 2010 and 2011 and $120 thousand for the six months ended June 30, 2012 for consulting services per the aforementioned agreement. No milestones under the license agreement were reached or expensed during the years ended December 31, 2009, 2010, 2011 or for the six months ended June 30, 2012.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i> </i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Collaboration Agreement with Solasia Pharma K.K.</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On March 7, 2011, we entered into a License and Collaboration Agreement with Solasia Pharma K.K., (“Solasia”).</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Pursuant to the License and Collaboration Agreement, we granted Solasia an exclusive license to develop and commercialize darinaparsin in both IV and oral forms and related organic arsenic molecules, in all indications for human use in a pan- Asian/Pacific territory comprised of Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand.</p> <p style="TEXT-ALIGN: center; MARGIN: 0pt 0px 0pt 6.6pt; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">As consideration for the license, we received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory, and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. We will also be entitled to receive double-digit royalty payments from Solasia based upon net sales of licensed products in the applicable territories, once commercialized, and a percentage of sublicense revenues generated by Solasia.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The upfront payment for research and development funding is earned over the period of effort. We currently estimate this period to be 75 months, which could be adjusted in the future.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Under the License and Collaboration Agreement, we provide Solasia with drug product to conduct clinical trials. These transfers are accounted for as a reduction of research and development costs and an increase in collaboration receivables.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The agreement provides that Solasia will be responsible for the development and commercialization of darinaparsin in the pan-Asian/Pacific territory.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><i>CRO Services Agreement with PPD Development, L.P.</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company and PPD Development, L.P. ("PPD") are parties to a master clinical research organization services agreement dated January 29, 2010, a related work order dated June 25, 2010 and a related work order dated April 8, 2011 under which PPD provides clinical research organization ("CRO") services in support of the Company's clinical trials. PPD is entitled to cumulative payments of up to $18.3 million under these arrangements, which is payable by the Company in varying amounts upon PPD achieving specified milestones. During the year ended December 31, 2010, the Company expensed $1.8 million upon contract execution and $1.1 million upon a clinical study commencement of enrollment in North America. During the year ended December 31, 2011, additional milestones related to commencing enrollment in Europe, Latin America and Asia, along with enrollment based milestones, were met and the Company recorded an aggregate $4.0 million expense. During the six months ended June 30, 2012, two enrollment related milestones were met and the Company recorded an expense of $2.6 million.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><i>CRO Services Agreement with Pharmaceutical Research Associates, Inc.</i></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company and Pharmaceutical Research Associates, Inc. (“PRA”) are parties to a master clinical research organization services agreement dated December 13, 2011 under which PRA provides CRO services in support of the Company's clinical trials. PRA is entitled to cumulative payments of up to $19.7 million under these arrangements, which is payable by the Company in varying amounts upon PRA achieving specified milestones. During the year ended December 31, 2011, the Company expensed $0.5 million upon execution of a letter of intent. During the six months ended June 30, 2012, the Company expensed $0.4 million upon execution of extensions of the foregoing letter of intent, $0.7 million upon work order execution and $1.0 million upon initial clinical study enrollment in the United States.</p> </div> </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock> | |||||||||||||||||||||
| <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_7"> 17457000 </us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims> | |||||||||||||||||||||
| <us-gaap:NetIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_5_8"> -235675000 </us-gaap:NetIncomeLoss> | |||||||||||||||||||||
| <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_58E2B92A-2342-47B9-B12D-DF3503D16E0F_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black"><b>2.</b></font> <b>Summary of Significant Accounting Policies</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b> </b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company’s significant accounting policies were identified in the Company’s Form 10-K for the fiscal year ended December 31, 2011.</p> </div> </us-gaap:SignificantAccountingPoliciesTextBlock> | |||||||||||||||||||||
| <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_1DAA92A9-34F5-4821-B0A2-EC8EA5645D14_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> For the three months</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> For the six months</td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic">(in thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 40%">Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">426</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">166</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">942</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">276</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 652</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 446</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,348</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,038</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Stock-based employee compensation expense</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,078</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 612</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,290</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,314</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div> </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock> | |||||||||||||||||||||
| <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_E782F607-A9DF-4341-9F03-4C6AA04842F9_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>10. Stock-Based Compensation</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> For the three months</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> For the six months</td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic">(in thousands)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 40%">Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">426</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">166</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">942</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">276</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 652</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 446</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,348</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,038</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Stock-based employee compensation expense</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,078</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 612</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,290</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,314</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">The Company granted 361,900 and 425,400 stock options during the three and six months ended June 30, 2012 that had a weighted-average grant date fair value of $3.51 and $3.48 per share, respectively. The Company granted 516,000 and 1,063,900 stock options during the three and six months ended June 30, 2011 that had a weighted-average grant date fair value of $4.69 and</font> $4.33 per <font style="COLOR: black">share, respectively.</font></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">At <font style="COLOR: black">June 30, 2012</font>, total unrecognized compensation costs related to unvested stock options outstanding amounted to $10.3 million. The cost is expected to be recognized over a weighted-average period of 1.59 years.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">For the</font> three months ended June 30, 2012 and 2011<font style="COLOR: black">, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:</font></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> For the three months ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Risk-free interest rate</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.93 - 1.10</td> <td style="TEXT-ALIGN: left">%</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">1.83 - 2.61</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Expected life in years</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">6</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">5.77 - 6</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected volatility</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">83.36 - 83.52</td> <td style="TEXT-ALIGN: left">%</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">84.4 - 87.4</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected dividend yield</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0</td> <td style="TEXT-ALIGN: left"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">Stock option activity under the Company’s stock option plan for the six months ended June 30, 2012 is as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic" nowrap="nowrap"> (in thousands, except share and per share data)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of<br /> Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted-<br /> Average Exercise<br /> Price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted-<br /> Average<br /> Contractual<br /> Term (Years)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Aggregate<br /> Intrinsic Value</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 40%">Outstanding, December 31, 2011</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">5,138,486</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">4.08</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">425,400</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">4.96</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Exercised</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(8,300</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">3.61</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Cancelled</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (158,432</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5.90</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Outstanding, June 30, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,397,154</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.10</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7.19</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10,320</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Vested and unvested expected to vest at June 30, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,340,550</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.10</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7.19</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 10,212</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Options exercisable, June 30, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,124,387</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.40</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.28</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 8,137</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Options exercisable, December 31, 2011</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,911,186</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3.21</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5.52</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,232</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Options available for future grant</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,678,000</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">A summary of the status of unvested restricted stock for the six months ended June 30, 2012 is as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of Shares</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted-Average<br /> Grant Date Fair Value</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 64%">Non-vested, December 31, 2011</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">950,906</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">4.34</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">170,302</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">4.51</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Vested</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(25,000</td> <td style="TEXT-ALIGN: left">)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">5.21</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Cancelled</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (66,360</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4.41</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Non-vested, June 30, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,029,848</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4.34</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">At June 30, 2012, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $6.4 million. The cost is expected to be recognized over a weighted-average period of 1.76 years.</p> </div> </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock> | |||||||||||||||||||||
| <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_30"> 16760000 </us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock> | |||||||||||||||||||||
| <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_16"> 15502000 </us-gaap:IncreaseDecreaseInAccruedLiabilities> | |||||||||||||||||||||
| <ziop:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_29"> 270726000 </ziop:ProceedsFromIssuanceOfCommonStockAndWarrantsNet> | |||||||||||||||||||||
| <ziop:IssuanceOfWarrantsToPlacementAgentInPublicOffering contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_3_39"> 47276000 </ziop:IssuanceOfWarrantsToPlacementAgentInPublicOffering> | |||||||||||||||||||||
| <ziop:CommonStockDisclosureTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_F979578C-53E7-462D-A4CB-0329F867FA12_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"><b>9. Common Stock</b></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">On January 20, 2012, the Company entered into an underwriting agreement with J. P. Morgan Securities LLC, as representative of the several underwriters named therein, relating to the issuance and sale of 9,650,000 shares of our common stock. The price to the public in the offering was $5.20 per share, and the underwriters agreed to purchase the shares from the Company pursuant to the underwriting agreement at a purchase price of $4.888 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,447,500 shares of common stock at a purchase price of $4.888 per share. The offering was made pursuant to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-177793) previously filed with the SEC, and a prospectus supplement thereunder. The underwriters purchased the 9,650,000 shares on January 25, 2012 and purchased an additional 464,401 shares on January 31, 2012 pursuant to the partial exercise of their option to purchase additional shares, resulting in our issuing a total of 10,114,401 shares. The net proceeds from the offering were approximately $49.2 million after deducting underwriting discounts and offering expenses payable by the Company.</p> </div> </ziop:CommonStockDisclosureTextBlock> | |||||||||||||||||||||
| <ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTableTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_0B1906E8-3AA2-4E50-823D-00221040D5B7_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">For the</font> three months ended June 30, 2012 and 2011<font style="COLOR: black">, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:</font></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"> For the three months ended June 30,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Risk-free interest rate</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.93 - 1.10</td> <td style="TEXT-ALIGN: left">%</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">1.83 - 2.61</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 70%">Expected life in years</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">6</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">5.77 - 6</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected volatility</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">83.36 - 83.52</td> <td style="TEXT-ALIGN: left">%</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">84.4 - 87.4</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected dividend yield</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0</td> <td style="TEXT-ALIGN: left"> </td> </tr> </table> </div> </ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsedTableTextBlock> | |||||||||||||||||||||
| <ziop:ScheduleOfStockholdersEquityNoteWarrantsAndCommonStockActivityTableTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_3B70F94F-5C13-4337-BB54-8FB34786353B_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">During the first six months of 2012, warrant exercises were as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Common</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Liability</td> <td style="FONT-WEIGHT: bold"> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Equity</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Liability</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Stock</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Reclassed</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Cash</td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic"> (in thousands, except share data)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Issued</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">to Equity</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Received</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 25%">Cash exercises</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">102,744</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">102,744</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">210</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Cashless exercises</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 12,329</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 373,617</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 89,859</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 412</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 115,073</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 373,617</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 192,603</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 412</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 210</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">During the first six months of 2011, warrant exercises were as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Common</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Liability</td> <td style="FONT-WEIGHT: bold"> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Equity</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Liability</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Stock</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Reclassed</td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"> Cash</td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-STYLE: italic"> (in thousands, except share data)</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Issued</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">to Equity</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Received</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 25%">Cash exercises</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">2,259,770</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">2,259,770</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">-</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">12,293</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Cashless exercises</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 39,832</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 144,905</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 59,308</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 265</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,299,602</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 144,905</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,319,078</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 265</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 12,293</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div> </ziop:ScheduleOfStockholdersEquityNoteWarrantsAndCommonStockActivityTableTextBlock> | |||||||||||||||||||||
| <ziop:ScheduleOfSecuritiesValuationAssumptionsTableTextBlock contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0" id="id_123082_8E4A9732-6D66-4B60-8880-EB974D1C84A1_1_0"> <div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">The following assumptions were used in the Binomial/Monte Carlo valuation model at June 30, 2012 and the Black-Scholes valuation model at June 30, 2011:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">June 30, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">June 30, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 64%">Risk-free interest rate</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.37</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 15%">0.18 - 1.01</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected life in years</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2.44</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0.92 - 3.43</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected volatility</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">70</td> <td style="TEXT-ALIGN: left">%</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">45 - 97</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Expected dividend yield</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">0</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td>Steps per year</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">12</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">N/A</td> <td style="TEXT-ALIGN: left"> </td> </tr> </table> </div> </ziop:ScheduleOfSecuritiesValuationAssumptionsTableTextBlock> | |||||||||||||||||||||
| <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0_505872x503547" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_1003_40"> 16760000 </us-gaap:ConversionOfStockAmountConverted1> | |||||||||||||||||||||
| <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE83398---1210-Q0004_STD_3217_20120630_0_505872x507958" unitRef="iso4217_USD" decimals="-3" id="id_123082_351FF973-5F7B-4F1E-9BE8-ABC6FB73FBA9_2003_41"> 9490000 </us-gaap:ConversionOfStockAmountConverted1> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20051231_0_512812x516172_553597x603793" unitRef="iso4217_USD" decimals="-3" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_2004_8"> 100000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested contextRef="eol_PE83398---1210-Q0004_STD_365_20051231_0_553597x603793_588157x537106" unitRef="iso4217_USD" decimals="0" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_6004_4"> 12555 </ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20061231_0_512812x516640_553597x603793" unitRef="iso4217_USD" decimals="-3" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_3003_9"> 250000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20061231_0_512812x516640_553597x603794" unitRef="iso4217_USD" decimals="-3" id="id_123082_403F8303-BB34-47EC-BCEB-EE495E65A537_1004_1"> 100000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20061231_0_512812x535922_553597x603793" unitRef="iso4217_USD" decimals="-3" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_4003_11"> 100000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20071231_0_512812x535922_553597x603793" unitRef="iso4217_USD" decimals="-3" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_4002_11"> 100000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_365_20071231_0_553597x603793" unitRef="iso4217_USD" decimals="-3" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_5002_6"> 120000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested contextRef="eol_PE83398---1210-Q0004_STD_365_20071231_0_553597x603793_588157x537107" unitRef="iso4217_USD" decimals="0" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_7002_5"> 25111 </ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20071231_0_553597x603797_588157x537110" unitRef="iso4217_USD" decimals="-3" id="id_123082_22A73969-B48A-425B-8537-C6363641173C_2002_3"> 625000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:WarrantsToPurchaseAggregateSharesOfCommonStock contextRef="eol_PE83398---1210-Q0004_STD_365_20091231_0" unitRef="shares" decimals="0" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_1_0"> 8206520 </ziop:WarrantsToPurchaseAggregateSharesOfCommonStock> | |||||||||||||||||||||
| <us-gaap:OtherExpenses contextRef="eol_PE83398---1210-Q0004_STD_365_20091231_0_501050x535531_588826x603798" unitRef="iso4217_USD" decimals="-3" id="id_123082_8BCC84EF-E3BD-481C-9E74-BCB7FF9C176D_3005_0"> 240000 </us-gaap:OtherExpenses> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExercisePeriod contextRef="eol_PE83398---1210-Q0004_STD_365_20091231_0_508454x534907" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_1001_3"> P6M </ziop:ClassOfWarrantOrRightExercisePeriod> | |||||||||||||||||||||
| <ziop:WarrantExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_365_20091231_0_508454x534907" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_1001_2"> 4.02 </ziop:WarrantExercisePrice> | |||||||||||||||||||||
| <ziop:WarrantsIssuedInInitialPublicOffering contextRef="eol_PE83398---1210-Q0004_STD_365_20091231_0_508454x534907" unitRef="shares" decimals="0" id="id_123082_D1134BFE-62A5-4935-B02F-B620689D44C3_1001_1"> 464520 </ziop:WarrantsIssuedInInitialPublicOffering> | |||||||||||||||||||||
| <us-gaap:PaymentsForRoyalties contextRef="eol_PE83398---1210-Q0004_STD_365_20091231_0_553597x603795" unitRef="iso4217_USD" decimals="-3" id="id_123082_985EAD3E-A512-4830-B0CB-B16BD69732B9_2004_2"> 25000 </us-gaap:PaymentsForRoyalties> | |||||||||||||||||||||
| <us-gaap:OtherExpenses contextRef="eol_PE83398---1210-Q0004_STD_365_20101231_0_501050x535531_588826x603798" unitRef="iso4217_USD" decimals="-3" id="id_123082_8BCC84EF-E3BD-481C-9E74-BCB7FF9C176D_3004_0"> 240000 </us-gaap:OtherExpenses> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20101231_0_512812x518024_553597x603794" unitRef="iso4217_USD" decimals="-3" id="id_123082_403F8303-BB34-47EC-BCEB-EE495E65A537_2002_6"> 300000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested contextRef="eol_PE83398---1210-Q0004_STD_365_20101231_0_512812x518024_553597x603794" unitRef="iso4217_USD" decimals="0" id="id_123082_403F8303-BB34-47EC-BCEB-EE495E65A537_2002_7"> 6904 </ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested> | |||||||||||||||||||||
| <us-gaap:PaymentsForRoyalties contextRef="eol_PE83398---1210-Q0004_STD_365_20101231_0_553597x603795" unitRef="iso4217_USD" decimals="-3" id="id_123082_985EAD3E-A512-4830-B0CB-B16BD69732B9_2005_2"> 25000 </us-gaap:PaymentsForRoyalties> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20101231_0_553597x603799_588157x537111" unitRef="iso4217_USD" decimals="-5" id="id_123082_5EA3AFB4-6CDB-4D09-A80A-78C56FE9C2A6_1003_2"> 1100000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20101231_0_553597x603799_588157x537112" unitRef="iso4217_USD" decimals="-5" id="id_123082_5EA3AFB4-6CDB-4D09-A80A-78C56FE9C2A6_2003_1"> 1800000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <us-gaap:OtherExpenses contextRef="eol_PE83398---1210-Q0004_STD_365_20111231_0_501050x535531_588826x603798" unitRef="iso4217_USD" decimals="-3" id="id_123082_8BCC84EF-E3BD-481C-9E74-BCB7FF9C176D_3003_0"> 240000 </us-gaap:OtherExpenses> | |||||||||||||||||||||
| <us-gaap:PaymentsForRoyalties contextRef="eol_PE83398---1210-Q0004_STD_365_20111231_0_553597x603795" unitRef="iso4217_USD" decimals="-3" id="id_123082_985EAD3E-A512-4830-B0CB-B16BD69732B9_2006_2"> 25000 </us-gaap:PaymentsForRoyalties> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20111231_0_553597x603799_588157x537113" unitRef="iso4217_USD" decimals="-5" id="id_123082_5EA3AFB4-6CDB-4D09-A80A-78C56FE9C2A6_3004_3"> 4000000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <ziop:MilestonePayment contextRef="eol_PE83398---1210-Q0004_STD_365_20111231_0_553597x603802_588157x537114" unitRef="iso4217_USD" decimals="-5" id="id_123082_8EF51F28-81E2-45E0-BC37-3C26952D800E_2003_1"> 500000 </ziop:MilestonePayment> | |||||||||||||||||||||
| <us-gaap:LicenseCosts contextRef="eol_PE83398---1210-Q0004_STD_366_20041231_0_499645x560796_553597x603793" unitRef="iso4217_USD" decimals="-3" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_1005_0"> 125000 </us-gaap:LicenseCosts> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE83398---1210-Q0004_STD_366_20041231_0_553597x603793" unitRef="shares" decimals="INF" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_5005_1"> 250487 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod> | |||||||||||||||||||||
| <ziop:OptionsToPurchaseCommonStock contextRef="eol_PE83398---1210-Q0004_STD_366_20041231_0_553597x603793" unitRef="shares" decimals="0" id="id_123082_3D389341-1FE9-4547-A021-639C965B01B3_5005_2"> 50222 </ziop:OptionsToPurchaseCommonStock> | |||||||||||||||||||||
| <ziop:OptionsToPurchaseCommonStock contextRef="eol_PE83398---1210-Q0004_STD_366_20041231_0_553597x603794" unitRef="shares" decimals="0" id="id_123082_403F8303-BB34-47EC-BCEB-EE495E65A537_3005_2"> 27616 </ziop:OptionsToPurchaseCommonStock> | |||||||||||||||||||||
| <ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested contextRef="eol_PE83398---1210-Q0004_STD_366_20041231_0_553597x603794" unitRef="iso4217_USD" decimals="0" id="id_123082_403F8303-BB34-47EC-BCEB-EE495E65A537_3005_4"> 6904 </ziop:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVested> | |||||||||||||||||||||
| <us-gaap:PaymentsForRoyalties contextRef="eol_PE83398---1210-Q0004_STD_366_20081231_0_553597x603795" unitRef="iso4217_USD" decimals="-3" id="id_123082_985EAD3E-A512-4830-B0CB-B16BD69732B9_2003_2"> 25000 </us-gaap:PaymentsForRoyalties> | |||||||||||||||||||||
| <ziop:ClassOfWarrantOrRightExpiredInPeriod contextRef="eol_PE83398---1210-Q0004_STD_38_20120531_0" unitRef="shares" decimals="INF" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_2_2"> 579 </ziop:ClassOfWarrantOrRightExpiredInPeriod> | |||||||||||||||||||||
| <ziop:StockIssuedDuringPeriodSharesPublicOffering contextRef="eol_PE83398---1210-Q0004_STD_38_20120120_0_508454x534907" unitRef="shares" decimals="INF" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_1001_0"> 9650000 </ziop:StockIssuedDuringPeriodSharesPublicOffering> | |||||||||||||||||||||
| <ziop:OptionsToPurchaseCommonStock contextRef="eol_PE83398---1210-Q0004_STD_38_20120120_0_508454x534907" unitRef="shares" decimals="0" id="id_123082_2DEC8948-5D40-420B-B113-B13BFD92F25F_1001_4"> 1447500 </ziop:OptionsToPurchaseCommonStock> | |||||||||||||||||||||
| <ziop:CommonStockWarrantExercisePrice contextRef="eol_PE83398---1210-Q0004_STD_61_20091231_0_512768x505866" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_1005_7"> 2.04 </ziop:CommonStockWarrantExercisePrice> | |||||||||||||||||||||
| <ziop:CommonStockIssuablePricePerShare contextRef="eol_PE83398---1210-Q0004_STD_61_20091231_0_512768x531939" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_A2DDB62F-0ECD-46F6-B266-4894A6112A7F_2005_9"> 3.10 </ziop:CommonStockIssuablePricePerShare> | |||||||||||||||||||||
| <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE83398---1210-Q0004_STD_730_20061221_0_504957x514053_553597x603795" unitRef="iso4217_USD" decimals="-3" id="id_123082_985EAD3E-A512-4830-B0CB-B16BD69732B9_1002_0"> 200000 </us-gaap:ResearchAndDevelopmentExpense> | |||||||||||||||||||||
| <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE83398---1210-Q0004_STD_730_20061221_0_553597x603795_588157x534110" unitRef="iso4217_USD" decimals="-3" id="id_123082_985EAD3E-A512-4830-B0CB-B16BD69732B9_3002_1"> 25000 </us-gaap:ResearchAndDevelopmentExpense> | |||||||||||||||||||||
| <us-gaap:OperatingIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_5"> -12848000 </us-gaap:OperatingIncomeLoss> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_6"> 9000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <us-gaap:ContractsRevenue contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_0"> 200000 </us-gaap:ContractsRevenue> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingGainsLosses contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_7"> 2115000 </us-gaap:OtherNonoperatingGainsLosses> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="pure" decimals="2" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_2_7"> 0.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="pure" decimals="4" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_2_0"> 0.0183 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_2_2"> 612000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_4"> 13048000 </us-gaap:OperatingCostsAndExpenses> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareDiluted contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_10"> -0.16 </us-gaap:EarningsPerShareDiluted> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="pure" decimals="4" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_2_5"> 0.8440 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum> | |||||||||||||||||||||
| <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_3"> 3923000 </us-gaap:GeneralAndAdministrativeExpense> | |||||||||||||||||||||
| <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="shares" decimals="0" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_12"> 67229098 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareBasic contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_9"> -0.16 </us-gaap:EarningsPerShareBasic> | |||||||||||||||||||||
| <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_2"> 9125000 </us-gaap:ResearchAndDevelopmentExpense> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="pure" decimals="4" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_2_6"> 0.8740 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum> | |||||||||||||||||||||
| <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="shares" decimals="0" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_11"> 67229098 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="pure" decimals="4" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_2_1"> 0.0261 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum> | |||||||||||||||||||||
| <us-gaap:NetIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_2_8"> -10724000 </us-gaap:NetIncomeLoss> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="shares" decimals="INF" id="id_123082_08C2C2CC-51D2-4B3B-BD6F-15DF336D63ED_3_0"> 516000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_08C2C2CC-51D2-4B3B-BD6F-15DF336D63ED_3_1"> 4.69 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0_498752x506779" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_1002_0"> 166000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0_498752x510320" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_2002_1"> 446000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0_504957x513639" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_1002_4"> P5Y9M7D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0_504957x514053" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_2002_3"> P6Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_91_20110630_0_510508x586161" unitRef="iso4217_USD" decimals="-5" id="id_123082_D7DD69C9-B454-427F-BA6E-D9677A8EA770_1001_0"> 2100000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <us-gaap:OperatingIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_5"> -22966000 </us-gaap:OperatingIncomeLoss> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_6"> 3000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <us-gaap:ContractsRevenue contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_0"> 200000 </us-gaap:ContractsRevenue> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingGainsLosses contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_7"> -650000 </us-gaap:OtherNonoperatingGainsLosses> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="pure" decimals="2" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_1_7"> 0.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="pure" decimals="4" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_1_0"> 0.0093 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_1_2"> 1078000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:OperatingCostsAndExpenses contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_4"> 23166000 </us-gaap:OperatingCostsAndExpenses> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareDiluted contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_10"> -0.30 </us-gaap:EarningsPerShareDiluted> | |||||||||||||||||||||
| <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_1_2"> P6Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="pure" decimals="4" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_1_5"> 0.8336 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum> | |||||||||||||||||||||
| <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_3"> 4902000 </us-gaap:GeneralAndAdministrativeExpense> | |||||||||||||||||||||
| <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="shares" decimals="0" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_12"> 78514718 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> | |||||||||||||||||||||
| <us-gaap:EarningsPerShareBasic contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_9"> -0.30 </us-gaap:EarningsPerShareBasic> | |||||||||||||||||||||
| <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_2"> 18264000 </us-gaap:ResearchAndDevelopmentExpense> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="pure" decimals="4" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_1_6"> 0.8352 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum> | |||||||||||||||||||||
| <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="shares" decimals="0" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_11"> 78514718 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="pure" decimals="4" id="id_123082_CDADE219-F59C-4896-8DF4-AAE3645219AA_1_1"> 0.0110 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum> | |||||||||||||||||||||
| <us-gaap:NetIncomeLoss contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD" decimals="-3" id="id_123082_2B8CEF35-BEFA-413A-89CF-C8F31CA024E1_1_8"> -23613000 </us-gaap:NetIncomeLoss> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="shares" decimals="INF" id="id_123082_08C2C2CC-51D2-4B3B-BD6F-15DF336D63ED_1_0"> 361900 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_123082_08C2C2CC-51D2-4B3B-BD6F-15DF336D63ED_1_1"> 3.51 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0_498752x506779" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_1001_0"> 426000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:ShareBasedCompensation contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0_498752x510320" unitRef="iso4217_USD" decimals="-3" id="id_123082_241F7C40-C968-4830-8624-13D05B294A64_2001_1"> 652000 </us-gaap:ShareBasedCompensation> | |||||||||||||||||||||
| <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE83398---1210-Q0004_STD_91_20120630_0_510508x586161" unitRef="iso4217_USD" decimals="-5" id="id_123082_D7DD69C9-B454-427F-BA6E-D9677A8EA770_1002_0"> -600000 </us-gaap:OtherNonoperatingIncomeExpense> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20120630_0_510508x586161"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis"> ziop:WarrantLiabilityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20120630_0_498752x510320"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20120630_0_498752x506779"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20120630_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20110630_0_510508x586161"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis"> ziop:WarrantLiabilityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20110630_0_504957x514053"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20110630_0_504957x513639"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20110630_0_498752x510320"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20110630_0_498752x506779"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_91_20110630_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-04-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_730_20061221_0_553597x603795_588157x534110"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:SouthernResearchInstituteMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:ExecutionOfSubscriptionAgreementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2004-12-22 </startDate> | |||||||||||||||||||||
| <endDate> 2006-12-21 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_730_20061221_0_504957x514053_553597x603795"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:SouthernResearchInstituteMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2004-12-22 </startDate> | |||||||||||||||||||||
| <endDate> 2006-12-21 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_61_20091231_0_512768x531939"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ziop:PublicOfferingMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2009-11-01 </startDate> | |||||||||||||||||||||
| <endDate> 2009-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_61_20091231_0_512768x505866"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2009-11-01 </startDate> | |||||||||||||||||||||
| <endDate> 2009-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_38_20120120_0_508454x534907"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:UnderwriterMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-12-14 </startDate> | |||||||||||||||||||||
| <endDate> 2012-01-20 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_38_20120531_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-04-24 </startDate> | |||||||||||||||||||||
| <endDate> 2012-05-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_366_20081231_0_553597x603795"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:SouthernResearchInstituteMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2008-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2008-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_366_20041231_0_553597x603794"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:DEKKTecIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2004-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2004-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_366_20041231_0_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2004-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2004-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_366_20041231_0_499645x560796_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis"> ziop:UpFrontPaymentMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2004-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2004-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20111231_0_553597x603802_588157x537114"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PharmaceuticalResearchAssociatesIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupNineMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20111231_0_553597x603799_588157x537113"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PPDDevelopmentLPMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupEightMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20111231_0_553597x603795"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:SouthernResearchInstituteMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20111231_0_501050x535531_588826x603798"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:HarmonHillLlcMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> ziop:CollaborationAgreementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20101231_0_553597x603799_588157x537112"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PPDDevelopmentLPMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupSevenMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2010-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2010-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20101231_0_553597x603799_588157x537111"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PPDDevelopmentLPMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupSixMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2010-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2010-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20101231_0_553597x603795"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:SouthernResearchInstituteMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2010-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2010-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20101231_0_512812x518024_553597x603794"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:DEKKTecIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> ziop:PhaseThreeMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2010-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2010-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20101231_0_501050x535531_588826x603798"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:HarmonHillLlcMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> ziop:CollaborationAgreementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2010-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2010-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20091231_0_553597x603795"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:SouthernResearchInstituteMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2009-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2009-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20091231_0_508454x534907"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:UnderwriterMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2009-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2009-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20091231_0_501050x535531_588826x603798"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:HarmonHillLlcMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> ziop:CollaborationAgreementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2009-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2009-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20091231_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2009-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2009-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20071231_0_553597x603797_588157x537110"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:BaxterHealthcareCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupFiveMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2007-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2007-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20071231_0_553597x603793_588157x537107"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupTwoMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2007-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2007-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20071231_0_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2007-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2007-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20071231_0_512812x535922_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> ziop:IntellectualPropertyRightsMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2007-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2007-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20061231_0_512812x535922_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> ziop:IntellectualPropertyRightsMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2006-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2006-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20061231_0_512812x516640_553597x603794"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:DEKKTecIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> ziop:PhaseTwoMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2006-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2006-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20061231_0_512812x516640_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> ziop:PhaseTwoMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2006-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2006-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20051231_0_553597x603793_588157x537106"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupOneMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2005-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2005-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_365_20051231_0_512812x516172_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> ziop:PhaseOneMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2005-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2005-12-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_3217_20120630_0_505872x507958"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2003-09-10 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_3217_20120630_0_505872x503547"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:ConvertiblePreferredStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2003-09-10 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_3217_20120630_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2003-09-10 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20110106_0_553597x603123_575210x533712"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:IntrexonCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:PeriodTypeAxis"> ziop:QuarterlyPaymentMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2010-12-07 </startDate> | |||||||||||||||||||||
| <endDate> 2011-01-06 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20050531_0_512768x505866"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2005-05-01 </startDate> | |||||||||||||||||||||
| <endDate> 2005-05-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20050531_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2005-05-01 </startDate> | |||||||||||||||||||||
| <endDate> 2005-05-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20080408_0_501050x535531_575210x533711_588826x603798"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:HarmonHillLlcMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:PeriodTypeAxis"> ziop:MonthlyPaymentMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> ziop:CollaborationAgreementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2008-03-09 </startDate> | |||||||||||||||||||||
| <endDate> 2008-04-08 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20080408_0_501050x535531_512812x516640_588826x603798"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:HarmonHillLlcMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> ziop:PhaseTwoMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> ziop:CollaborationAgreementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2008-03-09 </startDate> | |||||||||||||||||||||
| <endDate> 2008-04-08 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20120131_0_508454x534907_547800x569860"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:SaleOfStockAxis"> ziop:TotalMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:UnderwriterMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-01-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20120131_0_508454x534907"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:UnderwriterMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-01-31 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20070223_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2007-01-24 </startDate> | |||||||||||||||||||||
| <endDate> 2007-02-23 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20061103_0_553597x603797"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:BaxterHealthcareCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2006-10-04 </startDate> | |||||||||||||||||||||
| <endDate> 2006-11-03 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_31_20040824_0_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2004-07-25 </startDate> | |||||||||||||||||||||
| <endDate> 2004-08-24 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_30_20041015_0_499645x560796_553597x603794"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:DEKKTecIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis"> ziop:UpFrontPaymentMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2004-09-16 </startDate> | |||||||||||||||||||||
| <endDate> 2004-10-15 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_30_20120716_0_506663x511390_510660x512888"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis"> us-gaap:EmployeeSeveranceMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-06-17 </startDate> | |||||||||||||||||||||
| <endDate> 2012-07-16 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_28_20100316_0_553597x603794_588157x537109"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:DEKKTecIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupFourMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2010-02-17 </startDate> | |||||||||||||||||||||
| <endDate> 2010-03-16 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_25_20120125_0_508454x534907"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:UnderwriterMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-01-25 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_25_20120125_0_507611x603123"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> ziop:IntrexonCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-01-25 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_588826x603784"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:SolasiaPharmaKKMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603802_588157x537116"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PharmaceuticalResearchAssociatesIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupElevenMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603802_588157x537115"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PharmaceuticalResearchAssociatesIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupTenMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603802_588157x537113"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PharmaceuticalResearchAssociatesIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupEightMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603799_588157x537113"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PPDDevelopmentLPMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupEightMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_553597x603123"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:IntrexonCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_512768x505866"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_510508x586161"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis"> ziop:WarrantLiabilityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_509379x586161"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:WarrantLiabilityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_509379x533570"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:EquityWarrantAssetMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_509379x531033"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:StockIssuedMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_508454x557649"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:NonVestedRestrictedStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_508454x507958"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_508454x506554"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_507611x603123"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> ziop:IntrexonCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x531072"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> ziop:EndOfPeriodMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x531071"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> ziop:BeginningOfPeriodMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x530731"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> ziop:AdditionalPaidInCapitalCommonStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x504626"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:OtherAdditionalCapitalMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x501348"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_507189x500343"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:AccumulatedDeficitDuringDevelopmentStageMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x534240_509379x586161"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:WarrantLiabilityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:NonCashMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x534240_509379x533570"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:EquityWarrantAssetMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:NonCashMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x534240_509379x531033"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:StockIssuedMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:NonCashMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x534240"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:NonCashMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x532266_509379x533570"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:EquityWarrantAssetMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:WarrantCashExerciseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x532266_509379x531033"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:StockIssuedMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:WarrantCashExerciseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x532266"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:WarrantCashExerciseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_505872x507958"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_501050x535531_588826x603798"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:HarmonHillLlcMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"> ziop:CollaborationAgreementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_499645x588173_588826x603784"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:SolasiaPharmaKKMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis"> ziop:DevelopmentMilestonePaymentsMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_499645x535137_588826x603784"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CollaborativeAgreementAxis"> ziop:SolasiaPharmaKKMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis"> ziop:SalesEventsMilestoneMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_498752x510320"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0_498752x506779"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_182_20120630_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2012-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2012-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_510508x586161"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:InstrumentAxis"> ziop:WarrantLiabilityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_509379x586161"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:WarrantLiabilityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_509379x533570"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:EquityWarrantAssetMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_509379x531033"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:StockIssuedMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_508454x557649"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:NonVestedRestrictedStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_508454x507958"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:WarrantMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_508454x506554"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x534240_509379x586161"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:WarrantLiabilityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:NonCashMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x534240_509379x533570"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:EquityWarrantAssetMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:NonCashMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x534240_509379x531033"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:StockIssuedMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:NonCashMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x534240"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:NonCashMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x532266_509379x533570"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:EquityWarrantAssetMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:WarrantCashExerciseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x532266_509379x531033"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis"> ziop:StockIssuedMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:WarrantCashExerciseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x532266"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> ziop:WarrantCashExerciseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_505872x507958"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_498752x510320"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"> us-gaap:GeneralAndAdministrativeExpenseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0_498752x506779"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"> us-gaap:ResearchAndDevelopmentExpenseMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_181_20110630_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <startDate> 2011-01-01 </startDate> | |||||||||||||||||||||
| <endDate> 2011-06-30 </endDate> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120120_0_508454x534907"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:UnderwriterMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-01-20 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0_510142x511009"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0_510142x508799"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x530731"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> ziop:AdditionalPaidInCapitalCommonStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x504626"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:OtherAdditionalCapitalMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x501348"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0_507189x500343"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:AccumulatedDeficitDuringDevelopmentStageMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0_506936x598178"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis"> ziop:LiabilitiesMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0_506936x504830"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis"> us-gaap:EquityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111231_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20111213_0_553597x603802"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PharmaceuticalResearchAssociatesIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-12-13 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20101231_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2010-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20100129_0_553597x603799"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:PPDDevelopmentLPMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2010-01-29 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20091231_0_512768x531939"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> ziop:PublicOfferingMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2009-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20091231_0_512768x505866"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2009-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20091231_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2009-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20061231_0_512768x505866"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2006-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20041231_0_553597x603794"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:DEKKTecIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2004-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20041231_0_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2004-12-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_553597x603795"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:SouthernResearchInstituteMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_553597x603793_588157x537108"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:RequirementOfEligibleFutureMilestonePaymentsAxis"> ziop:GroupThreeMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_553597x603793"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_510728x580425"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis"> ziop:MonteCarloOptionPricingModelMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_510142x511009"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_510142x508799"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_508454x557649"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> ziop:NonVestedRestrictedStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_507611x603123"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> ziop:IntrexonCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x530731"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> ziop:AdditionalPaidInCapitalCommonStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x504626"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:OtherAdditionalCapitalMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x501348"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_507189x500343"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis"> us-gaap:AccumulatedDeficitDuringDevelopmentStageMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_506936x598178"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis"> ziop:LiabilitiesMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_506936x504830"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis"> us-gaap:EquityMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0_504957x513639_510728x580425"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis"> ziop:MonteCarloOptionPricingModelMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120630_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20110630_0_510728x559133"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis"> ziop:BlackScholesOptionPricingModelMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20110630_0_504957x514053_510728x559133"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MaximumMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis"> ziop:BlackScholesOptionPricingModelMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20110630_0_504957x513639_510728x559133"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:RangeAxis"> us-gaap:MinimumMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis"> ziop:BlackScholesOptionPricingModelMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20110630_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-06-30 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20041015_0_553597x603794"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:DEKKTecIncMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2004-10-15 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20120729_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2012-07-29 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20050531_0_512768x505866"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis"> us-gaap:PrivatePlacementMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2005-05-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20050531_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2005-05-31 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20110307_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2011-03-07 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20070223_0"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2007-02-23 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20061103_0_499645x533554_553597x603797"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:BaxterHealthcareCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis"> ziop:RoyaltyPaymentsMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2006-11-03 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20061103_0_499645x511481_553597x603797"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:BaxterHealthcareCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis"> us-gaap:InventoriesMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2006-11-03 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <context id="eol_PE83398---1210-Q0004_STD_0_20061103_0_499645x505333_553597x603797"> | |||||||||||||||||||||
| <entity> | |||||||||||||||||||||
| <identifier scheme="http://www.sec.gov/CIK"> 0001107421 </identifier> | |||||||||||||||||||||
| <segment> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="ziop:CommitmentAndContingenciesAxis"> ziop:BaxterHealthcareCorporationMember </xbrldi:explicitMember> | |||||||||||||||||||||
| <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis"> us-gaap:AssetsMember </xbrldi:explicitMember> | |||||||||||||||||||||
| </segment> | |||||||||||||||||||||
| </entity> | |||||||||||||||||||||
| <period> | |||||||||||||||||||||
| <instant> 2006-11-03 </instant> | |||||||||||||||||||||
| </period> | |||||||||||||||||||||
| </context> | |||||||||||||||||||||
| <unit id="iso4217_USD"> | |||||||||||||||||||||
| <measure> iso4217:USD </measure> | |||||||||||||||||||||
| </unit> | |||||||||||||||||||||
| <unit id="iso4217_USD_per_Right"> | |||||||||||||||||||||
| <divide> | |||||||||||||||||||||
| <unitNumerator> | |||||||||||||||||||||
| <measure> iso4217:USD </measure> | |||||||||||||||||||||
| </unitNumerator> | |||||||||||||||||||||
| <unitDenominator> | |||||||||||||||||||||
| <measure> ziop:Right </measure> | |||||||||||||||||||||
| </unitDenominator> | |||||||||||||||||||||
| </divide> | |||||||||||||||||||||
| </unit> | |||||||||||||||||||||
| <unit id="iso4217_USD_per_shares"> | |||||||||||||||||||||
| <divide> | |||||||||||||||||||||
| <unitNumerator> | |||||||||||||||||||||
| <measure> iso4217:USD </measure> | |||||||||||||||||||||
| </unitNumerator> | |||||||||||||||||||||
| <unitDenominator> | |||||||||||||||||||||
| <measure> shares </measure> | |||||||||||||||||||||
| </unitDenominator> | |||||||||||||||||||||
| </divide> | |||||||||||||||||||||
| </unit> | |||||||||||||||||||||
| <unit id="shares"> | |||||||||||||||||||||
| <measure> shares </measure> | |||||||||||||||||||||
| </unit> | |||||||||||||||||||||
| <unit id="Year"> | |||||||||||||||||||||
| <measure> ziop:Year </measure> | |||||||||||||||||||||
| </unit> | |||||||||||||||||||||
| <unit id="pure"> | |||||||||||||||||||||
| <measure> pure </measure> | |||||||||||||||||||||
| </unit> | |||||||||||||||||||||
| <unit id="Patent"> | |||||||||||||||||||||
| <measure> ziop:Patent </measure> | |||||||||||||||||||||
| </unit> | |||||||||||||||||||||
| </xbrl> | |||||||||||||||||||||